BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mancuso MR, Davis R, Norberg SM, O’Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116:2610-2621. [PMID: 17016557 DOI: 10.1172/jci24612] [Cited by in Crossref: 606] [Cited by in F6Publishing: 650] [Article Influence: 40.4] [Reference Citation Analysis]
Number Citing Articles
1 Adnani L, Spinelli C, Tawil N, Rak J. Role of extracellular vesicles in cancer-specific interactions between tumour cells and the vasculature. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.11.003] [Reference Citation Analysis]
2 Swamy K. Vascular normalization and immunotherapy: Spawning a virtuous cycle. Front Oncol 2022;12:1002957. [DOI: 10.3389/fonc.2022.1002957] [Reference Citation Analysis]
3 Azad AK, Campbell KR, Zhabyeyev P, Oudit GY, Moore RB, Murray AG. Loss of apelin blocks the emergence of sprouting angiogenesis in experimental tumors. FASEB J 2022;36:e22560. [PMID: 36165236 DOI: 10.1096/fj.202200616RR] [Reference Citation Analysis]
4 Kerhervé M, Rosińska S, Trillet K, Zeinaty A, Feyeux M, Nedellec S, Gavard J. Neuropilin-1 modulates the 3D invasive properties of glioblastoma stem-like cells. Front Cell Dev Biol 2022;10:981583. [DOI: 10.3389/fcell.2022.981583] [Reference Citation Analysis]
5 Ju W, Xia R, Zhu D, Dou S, Zhu G, Dong M, Wang L, Sun Q, Zhao T, Zhou Z, Liang S, Huang Y, Tang Y, Wu S, Xia J, Chen S, Bai Y, Li J, Zhu Q, Zhong L. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-33080-8] [Reference Citation Analysis]
6 Kharaishvili G. Extracellular Matrix in Tumor Angiogenesis. Tumor Angiogenesis and Modulators 2022. [DOI: 10.5772/intechopen.104661] [Reference Citation Analysis]
7 Ortiz M, Wabel E, Mitchell K, Horibata S. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist 2022;5:304-16. [PMID: 35800369 DOI: 10.20517/cdr.2021.147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wrange EKM, Harders SMW. A rare case of metastatic atypical meningioma that highlights the shortcomings of treatment options at present. Acta Radiologica Open 2022;11:205846012211099. [DOI: 10.1177/20584601221109891] [Reference Citation Analysis]
9 Huang M, Lin Y, Wang C, Deng L, Chen M, Assaraf YG, Chen ZS, Ye W, Zhang D. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects. Drug Resist Updat 2022;64:100849. [PMID: 35842983 DOI: 10.1016/j.drup.2022.100849] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Schiffmann LM, Bruns CJ, Schmidt T. Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy. Front Oncol 2022;12:897927. [PMID: 35664794 DOI: 10.3389/fonc.2022.897927] [Reference Citation Analysis]
11 Wang X, Chen Z, Xu J, Tang S, An N, Jiang L, Zhang Y, Zhang S, Zhang Q, Shen Y, Chen S, Lan X, Wang T, Zhai L, Cao S, Guo S, Liu Y, Bi A, Chen Y, Gai X, Duan Y, Zheng Y, Fu Y, Li Y, Yuan L, Tong L, Mo K, Wang M, Lin SH, Tan M, Luo C, Chen Y, Liu J, Zhang Q, Li L, Huang M. SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Cell Res 2022. [PMID: 35459936 DOI: 10.1038/s41422-022-00650-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Abedi Z, MotieGhader H, Hosseini SS, Sheikh Beig Goharrizi MA, Masoudi-Nejad A. mRNA-miRNA bipartite networks reconstruction in different tissues of bladder cancer based on gene co-expression network analysis. Sci Rep 2022;12:5885. [PMID: 35393513 DOI: 10.1038/s41598-022-09920-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Benítez JM, García-mozos L, Santos A, Montáns FJ, Saucedo-mora L. A simple agent-based model to simulate 3D tumor-induced angiogenesis considering the evolution of the hypoxic conditions of the cells. Engineering with Computers 2022. [DOI: 10.1007/s00366-022-01625-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Farzaneh Behelgardi M, Gholami Shahvir Z, Asghari SM. Apoptosis induction in human lung and colon cancer cells via impeding VEGF signaling pathways. Mol Biol Rep 2022. [PMID: 35142981 DOI: 10.1007/s11033-022-07203-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Li L, Cheng L, Sa R, Qiu X, Chen L. Real-world insights into the efficacy and safety of tyrosine kinase inhibitors against thyroid cancers. Crit Rev Oncol Hematol 2022;:103624. [PMID: 35150866 DOI: 10.1016/j.critrevonc.2022.103624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Li H, Bi F, Beck A, Bobrovskaya L, Zhou X. ProBDNF Acts as an Angiogenesis Inhibitor. JBM 2022;10:219-235. [DOI: 10.4236/jbm.2022.104019] [Reference Citation Analysis]
17 Koltai T, Reshkin SJ, Cardone RA. Resistance to antiangiogenic treatments: A review. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy 2022. [DOI: 10.1016/b978-0-323-90190-1.00014-7] [Reference Citation Analysis]
18 Nagao RJ, Marcu R, Shin YJ, Lih D, Xue J, Arang N, Wei L, Akilesh S, Kaushansky A, Himmelfarb J, Zheng Y. Cyclosporine Induces Fenestra-Associated Injury in Human Renal Microvessels In Vitro. ACS Biomater Sci Eng . [DOI: 10.1021/acsbiomaterials.1c00986] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Jiang P, Zhang Y, Cui J, Wang X, Li Y. Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs. Thorac Cancer 2021. [PMID: 34855286 DOI: 10.1111/1759-7714.14261] [Reference Citation Analysis]
20 Toda S, Iwasaki H, Murayama D, Isoda M, Nakayama H, Suganuma N, Masudo K. Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report. J Med Case Rep 2021;15:556. [PMID: 34763724 DOI: 10.1186/s13256-021-03158-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Jacobsen NL, Norton CE, Shaw RL, Cornelison DDW, Segal SS. Myofibre injury induces capillary disruption and regeneration of disorganized microvascular networks. J Physiol 2021. [PMID: 34761825 DOI: 10.1113/JP282292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Enokida T, Tahara M. Management of VEGFR-Targeted TKI for Thyroid Cancer. Cancers (Basel) 2021;13:5536. [PMID: 34771698 DOI: 10.3390/cancers13215536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Murphy AD, Morgan RD, Clamp AR, Jayson GC. The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. Br J Cancer 2021. [PMID: 34716396 DOI: 10.1038/s41416-021-01605-5] [Reference Citation Analysis]
24 Sahebnasagh A, Nabavi SM, Kashani HRK, Abdollahian S, Habtemariam S, Rezabakhsh A. Anti-VEGF agents: As appealing targets in the setting of COVID-19 treatment in critically ill patients. Int Immunopharmacol 2021;101:108257. [PMID: 34673299 DOI: 10.1016/j.intimp.2021.108257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
25 Lee SH, Choi JY, Jung JH, Song IH, Park HS, Denora N, Leonetti F, Kim SE, Lee BC. Effect of Peptide Receptor Radionuclide Therapy in Combination with Temozolomide against Tumor Angiogenesis in a Glioblastoma Model. Cancers (Basel) 2021;13:5029. [PMID: 34638512 DOI: 10.3390/cancers13195029] [Reference Citation Analysis]
26 Lefevere E, Van Hove I, Sergeys J, Steel DHW, Schlingemann R, Moons L, Klaassen I. PDGF as an Important Initiator for Neurite Outgrowth Associated with Fibrovascular Membranes in Proliferative Diabetic Retinopathy. Curr Eye Res 2021;:1-10. [PMID: 34612091 DOI: 10.1080/02713683.2021.1966479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Siddiqui AJ, Khan MF, Hamadou WS, Goyal M, Jahan S, Jamal A, Ashraf SA, Sharma P, Sachidanandan M, Badraoui R, Chaubey KK, Snoussi M, Adnan M. Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug against Schistosoma-Associated Bladder Cancer Targeting Protein Signaling: Computational Drug Repositioning Approach. Medicina (Kaunas) 2021;57:1058. [PMID: 34684095 DOI: 10.3390/medicina57101058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Jiang HJ, Chang YH, Chen YH, Wu CW, Wang PW, Hsiao PJ. Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma - A Real-World Experience. Cancer Manag Res 2021;13:7139-48. [PMID: 34548818 DOI: 10.2147/CMAR.S326255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Reis-Sobreiro M, Teixeira da Mota A, Jardim C, Serre K. Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages. Cells 2021;10:2364. [PMID: 34572013 DOI: 10.3390/cells10092364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Roda N, Blandano G, Pelicci PG. Blood Vessels and Peripheral Nerves as Key Players in Cancer Progression and Therapy Resistance. Cancers (Basel) 2021;13:4471. [PMID: 34503281 DOI: 10.3390/cancers13174471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Jacobsen NL, Norton CE, Shaw RL, Cornelison D, Segal SS. Myofiber injury induces capillary disruption and regeneration of disorganized microvascular networks.. [DOI: 10.1101/2021.08.02.454805] [Reference Citation Analysis]
32 Singleton DC, Macann A, Wilson WR. Therapeutic targeting of the hypoxic tumour microenvironment. Nat Rev Clin Oncol 2021. [PMID: 34326502 DOI: 10.1038/s41571-021-00539-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 51.0] [Reference Citation Analysis]
33 Ribatti D, Solimando AG, Pezzella F. The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer. Cancers (Basel) 2021;13:3433. [PMID: 34298648 DOI: 10.3390/cancers13143433] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 24.0] [Reference Citation Analysis]
34 Inoue T, Byrne T, Inoue M, Tait ME, Wall P, Wang A, Dermyer MR, Laklai H, Binder JJ, Lees C, Hollingsworth R, Maruri-Avidal L, Kirn DH, McDonald DM. Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing. Mol Cancer Ther 2021;20:1481-94. [PMID: 34045231 DOI: 10.1158/1535-7163.MCT-20-0863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Huang M, Chen M, Qi M, Ye G, Pan J, Shi C, Yang Y, Zhao L, Mo X, Zhang Y, Li Y, Zhong J, Lu W, Li X, Zhang J, Lin J, Luo L, Liu T, Tang PM, Hong A, Cao Y, Ye W, Zhang D. Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. J Extracell Vesicles 2021;10:e12096. [PMID: 34035882 DOI: 10.1002/jev2.12096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
36 Tsai TH, Chen YJ, Wang LY, Hsieh CH. Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation. Pharmaceutics 2021;13:386. [PMID: 33805831 DOI: 10.3390/pharmaceutics13030386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
37 Hansen TF, Qvortrup C, Pfeiffer P. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers (Basel) 2021;13:1031. [PMID: 33804554 DOI: 10.3390/cancers13051031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
38 Toda S, Iwasaki H, Murayama D, Nakayama H, Suganuma N, Masudo K. Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer. Mol Clin Oncol 2021;14:81. [PMID: 33758662 DOI: 10.3892/mco.2021.2243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Mukwaya A, Jensen L, Lagali N. Relapse of pathological angiogenesis: functional role of the basement membrane and potential treatment strategies. Exp Mol Med 2021;53:189-201. [PMID: 33589713 DOI: 10.1038/s12276-021-00566-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
40 Hooglugt A, van der Stoel MM, Boon RA, Huveneers S. Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature. Front Oncol 2020;10:612802. [PMID: 33614496 DOI: 10.3389/fonc.2020.612802] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
41 Grant ZL, Whitehead L, Wong VH, He Z, Yan RY, Miles AR, Benest AV, Bates DO, Prahst C, Bentley K, Bui BV, Symons RC, Coultas L. Blocking endothelial apoptosis revascularizes the retina in a model of ischemic retinopathy. J Clin Invest 2020;130:4235-51. [PMID: 32427589 DOI: 10.1172/JCI127668] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
42 Yanagisawa H, Sugimoto M, Miyashita T. Mathematical simulation of tumour angiogenesis: angiopoietin balance is a key factor in vessel growth and regression. Sci Rep 2021;11:419. [PMID: 33432093 DOI: 10.1038/s41598-020-79824-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Ribatti D. Tumor pericytes. Tumor Microenvironment Regulation of Tumor Expansion 2021. [DOI: 10.1016/b978-0-12-822803-6.00012-0] [Reference Citation Analysis]
44 Ohara T, Sasaki T, Endo H, Kanamori R, Imai H, Nagasawa Y, Yamanaka H, Hosonuma S, Kuji S, Deura I, Tozawa A, Suzuki N. Efficacy of Gemcitabine and Bevacizumab Combination Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Analysis. J St Marianna Univ 2021;12:69-75. [DOI: 10.17264/stmarieng.12.69] [Reference Citation Analysis]
45 Yeom DH, Lee YS, Ryu I, Lee S, Sung B, Lee HB, Kim D, Ahn JH, Ha E, Choi YS, Lee SH, You WK. ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models. Int J Mol Sci 2020;22:E241. [PMID: 33383646 DOI: 10.3390/ijms22010241] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
46 Iwasaki H, Toda S, Murayama D, Kato S, Matsui A. Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis. Mol Clin Oncol 2021;14:28. [PMID: 33414909 DOI: 10.3892/mco.2020.2190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
47 Swietlik EM, Prapa M, Martin JM, Pandya D, Auckland K, Morrell NW, Gräf S. 'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. Genes (Basel) 2020;11:E1408. [PMID: 33256119 DOI: 10.3390/genes11121408] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
48 Summers ME, Richmond BW, Kropski JA, Majka SA, Bastarache JA, Hatzopoulos AK, Bylund J, Ghosh M, Petrache I, Foronjy RF, Geraghty P, Majka SM. Balanced Wnt/Dickkopf-1 signaling by mesenchymal vascular progenitor cells in the microvascular niche maintains distal lung structure and function. Am J Physiol Cell Physiol 2021;320:C119-31. [PMID: 33085496 DOI: 10.1152/ajpcell.00277.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
49 Riggin CN, Rodriguez AB, Weiss SN, Raja HA, Chen M, Schultz SM, Sehgal CM, Soslowsky LJ. Modulation of vascular response after injury in the rat Achilles tendon alters healing capacity. J Orthop Res 2021;39:2000-16. [PMID: 32936495 DOI: 10.1002/jor.24861] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
50 Winter MP, Sharma S, Altmann J, Seidl V, Panzenböck A, Alimohammadi A, Zelniker T, Redwan B, Nagel F, Santer D, Stieglbauer A, Podesser B, Sibilia M, Helbich T, Prager G, Ilhan-Mutlu A, Preusser M, Lang IM. Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension. Basic Res Cardiol 2020;115:58. [PMID: 32880713 DOI: 10.1007/s00395-020-0811-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
51 Azad AK, Zhabyeyev P, Vanhaesebroeck B, Eitzen G, Oudit GY, Moore RB, Murray AG. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth. Oncogene 2020;39:6480-92. [PMID: 32879446 DOI: 10.1038/s41388-020-01444-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
52 Sasaki A, Harano K, Kogawa T, Matsubara N, Naito Y, Hosono A, Mukai H, Yoshino T, Mukohara T. Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer. Case Rep Oncol Med 2020;2020:7231358. [PMID: 32612862 DOI: 10.1155/2020/7231358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Payne LB, Hoque M, Houk C, Darden J, Chappell JC. Pericytes in Vascular Development. Curr Tissue Microenviron Rep 2020;1:143-54. [PMID: 33748774 DOI: 10.1007/s43152-020-00014-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
54 Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer 2020;11:4474-94. [PMID: 32489466 DOI: 10.7150/jca.44313] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 28.0] [Reference Citation Analysis]
55 Iwasaki H, Toda S, Ito H, Nemoto D, Murayama D, Okubo Y, Hayashi H, Yokose T. A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy. Case Rep Endocrinol 2020;2020:6438352. [PMID: 32455032 DOI: 10.1155/2020/6438352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
56 Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 2020;11:2135. [PMID: 32358509 DOI: 10.1038/s41467-020-15959-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 31.5] [Reference Citation Analysis]
57 Le CC, Bennasroune A, Langlois B, Salesse S, Boulagnon-Rombi C, Morjani H, Dedieu S, Appert-Collin A. Functional Interplay Between Collagen Network and Cell Behavior Within Tumor Microenvironment in Colorectal Cancer. Front Oncol 2020;10:527. [PMID: 32426274 DOI: 10.3389/fonc.2020.00527] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
58 Corliss BA, Ray HC, Doty RW, Mathews C, Sheybani N, Fitzgerald K, Prince R, Kelly-Goss MR, Murfee WL, Chappell J, Owens GK, Yates PA, Peirce SM. Pericyte Bridges in Homeostasis and Hyperglycemia. Diabetes 2020;69:1503-17. [PMID: 32321760 DOI: 10.2337/db19-0471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
59 Liu M, Li H, Wang X, Jing L, Jiang P, Li Y. Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients. Cancer Med 2020;9:2660-73. [PMID: 32073228 DOI: 10.1002/cam4.2923] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
60 Das SK, Maji S, Wechman SL, Bhoopathi P, Pradhan AK, Talukdar S, Sarkar D, Landry J, Guo C, Wang XY, Cavenee WK, Emdad L, Fisher PB. MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis. Pharmacol Res 2020;155:104695. [PMID: 32061839 DOI: 10.1016/j.phrs.2020.104695] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
61 Ribatti D, Pezzella F. Sprouting and nonsprouting angiogenesis in tumors. Tumor Vascularization 2020. [DOI: 10.1016/b978-0-12-819494-2.00001-8] [Reference Citation Analysis]
62 Parmar A, Bjarnason GA. Individualization of Dose and Schedule Based On Toxicity for Oral VEGF Drugs in Kidney Cancer. KCA 2019;3:213-25. [DOI: 10.3233/kca-190077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
63 Brossa A, Buono L, Fallo S, Fiorio Pla A, Munaron L, Bussolati B. Alternative Strategies to Inhibit Tumor Vascularization. Int J Mol Sci 2019;20:E6180. [PMID: 31817884 DOI: 10.3390/ijms20246180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
64 Koltai T, Cardone RA, Reshkin SJ. Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer. Int J Mol Sci 2019;20:E5438. [PMID: 31683667 DOI: 10.3390/ijms20215438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Ciruelos E, Pérez-García JM, Gavilá J, Rodríguez A, de la Haba-Rodriguez J. Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept. Clin Drug Investig 2019;39:595-606. [PMID: 31054086 DOI: 10.1007/s40261-019-00790-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
66 Mukwaya A, Mirabelli P, Lennikov A, Thangavelu M, Ntzouni M, Jensen L, Peebo B, Lagali N. Revascularization after angiogenesis inhibition favors new sprouting over abandoned vessel reuse. Angiogenesis 2019;22:553-67. [PMID: 31486010 DOI: 10.1007/s10456-019-09679-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
67 Sattiraju A, Mintz A. Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions. Adv Exp Med Biol 2019;1147:65-91. [PMID: 31147872 DOI: 10.1007/978-3-030-16908-4_2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
68 Corliss BA, Ray HC, Doty R, Mathews C, Sheybani N, Fitzgerald K, Prince R, Kelly-goss M, Murfee WL, Chappell J, Owens G, Yates P, Peirce SM. Pericyte Bridges in Homeostasis and Hyperglycemia: Reconsidering Pericyte Dropout and Microvascular Structures.. [DOI: 10.1101/704007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Bonanno L, Pavan A, Pasello G, Indraccolo S. Editorial on "The AvaALL Randomized Clinical Trial". J Thorac Dis 2019;11:S1237-40. [PMID: 31245096 DOI: 10.21037/jtd.2019.02.62] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Lee ATJ, Jones RL, Huang PH. Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther 2019;4:16. [PMID: 31123606 DOI: 10.1038/s41392-019-0049-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
71 Ali Z, Mukwaya A, Biesemeier A, Ntzouni M, Ramsköld D, Giatrellis S, Mammadzada P, Cao R, Lennikov A, Marass M, Gerri C, Hildesjö C, Taylor M, Deng Q, Peebo B, Del Peso L, Kvanta A, Sandberg R, Schraermeyer U, Andre H, Steffensen JF, Lagali N, Cao Y, Kele J, Jensen LD. Intussusceptive Vascular Remodeling Precedes Pathological Neovascularization. Arterioscler Thromb Vasc Biol 2019;39:1402-18. [PMID: 31242036 DOI: 10.1161/ATVBAHA.118.312190] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
72 Riggin CN, Schultz SM, Sehgal CM, Soslowsky LJ. Ultrasound Evaluation of Anti-Vascular Endothelial Growth Factor-Induced Changes in Vascular Response Following Tendon Injury. Ultrasound Med Biol 2019;45:1841-9. [PMID: 31053429 DOI: 10.1016/j.ultrasmedbio.2019.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
73 Deng P, Hu C, Xiong Z, Li Y, Jiang J, Yang H, Tang Y, Cao L, Lu R. Epigallocatechin-3-gallate-induced vascular normalization in A549-cell xenograft-bearing nude mice: therapeutic efficacy in combination with chemotherapy. Cancer Manag Res 2019;11:2425-39. [PMID: 30988640 DOI: 10.2147/CMAR.S187750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
74 Wang G, Huang Y, Wu Z, Zhao C, Cong H, Ju S, Wang X. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib. Biosci Rep 2019;39:BSR20181786. [PMID: 30674639 DOI: 10.1042/BSR20181786] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
75 Chang S, Jain V, Chen T, Patel AS, Pidugu HB, Lin Y, Wu M, Huang J, Wu H, Shah A, Su T, Lee T. Design and Synthesis of 1,2-Bis(hydroxymethyl)pyrrolo[2,1- a ]phthalazine Hybrids as Potent Anticancer Agents that Inhibit Angiogenesis and Induce DNA Interstrand Cross-links. J Med Chem 2019;62:2404-18. [DOI: 10.1021/acs.jmedchem.8b01689] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
76 Rosenberger L, Ezquer M, Lillo-Vera F, Pedraza PL, Ortúzar MI, González PL, Figueroa-Valdés AI, Cuenca J, Ezquer F, Khoury M, Alcayaga-Miranda F. Stem cell exosomes inhibit angiogenesis and tumor growth of oral squamous cell carcinoma. Sci Rep 2019;9:663. [PMID: 30679544 DOI: 10.1038/s41598-018-36855-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 20.0] [Reference Citation Analysis]
77 Nahleh Z, Botrus G, Dwivedi A, Jennings M, Nagy S, Tfayli A. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol 2019;10:357-65. [PMID: 30847174 DOI: 10.3892/mco.2019.1796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
78 Jayson G, O’connor J. Imaging Tumor Angiogenesis. Tumor Angiogenesis 2019. [DOI: 10.1007/978-3-319-33673-2_7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Ribatti D. Anti-angiogenic Cancer Therapy: Development of Resistance. Tumor Angiogenesis 2019. [DOI: 10.1007/978-3-319-33673-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Bamias A, Karavasilis V, Gavalas N, Tzannis K, Samantas E, Aravantinos G, Koutras A, Gkerzelis I, Kostouros E, Koutsoukos K, Zagouri F, Fountzilas G, Dimopoulos MA. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. Int J Clin Oncol 2019;24:411-9. [PMID: 30374686 DOI: 10.1007/s10147-018-1361-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
81 Delgado-Ureña M, Ortega FG, de Miguel-Pérez D, Rodriguez-Martínez A, García-Puche JL, Ilyine H, Lorente JA, Exposito-Hernandez J, Garrido-Navas MC, Delgado-Ramirez M, Serrano MJ. Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients. J Transl Med 2018;16:251. [PMID: 30189880 DOI: 10.1186/s12967-018-1624-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
82 Nguyen EH, Murphy WL. Customizable biomaterials as tools for advanced anti-angiogenic drug discovery. Biomaterials 2018;181:53-66. [PMID: 30077137 DOI: 10.1016/j.biomaterials.2018.07.041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
83 Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med 2017;9:eaan5616. [PMID: 28978752 DOI: 10.1126/scitranslmed.aan5616] [Cited by in Crossref: 152] [Cited by in F6Publishing: 160] [Article Influence: 38.0] [Reference Citation Analysis]
84 Rossow L, Veitl S, Vorlová S, Wax JK, Kuhn AE, Maltzahn V, Upcin B, Karl F, Hoffmann H, Gätzner S, Kallius M, Nandigama R, Scheld D, Irmak S, Herterich S, Zernecke A, Ergün S, Henke E. LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to chemotherapy. Oncogene 2018;37:4921-40. [PMID: 29780168 DOI: 10.1038/s41388-018-0320-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 9.5] [Reference Citation Analysis]
85 Rojas MA, Shen ZT, Caldwell RB, Sigalov AB. Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy. Biochim Biophys Acta Mol Basis Dis 2018;1864:2761-8. [PMID: 29730341 DOI: 10.1016/j.bbadis.2018.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
86 Donskov F, Jensen NV, Smidt-Hansen T, Brøndum L, Geertsen P. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. Acta Oncol 2018;57:589-94. [PMID: 29392960 DOI: 10.1080/0284186X.2018.1433324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
87 Brossa A, Buono L, Bussolati B. Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells. Oncotarget 2018;9:22680-92. [PMID: 29854307 DOI: 10.18632/oncotarget.25206] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
88 Logun M, Zhao W, Mao L, Karumbaiah L. Microfluidics in Malignant Glioma Research and Precision Medicine. Adv Biosyst 2018;2:1700221. [PMID: 29780878 DOI: 10.1002/adbi.201700221] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
89 Maráz A, Cserháti A, Uhercsák G, Szilágyi É, Varga Z, Révész J, Kószó R, Varga L, Kahán Z. Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. BMC Cancer 2018;18:296. [PMID: 29544452 DOI: 10.1186/s12885-018-4209-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
90 Becherirat S, Valamanesh F, Karimi M, Faussat AM, Launay JM, Pimpie C, Therwath A, Pocard M. Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes. Transl Oncol 2018;11:406-15. [PMID: 29459325 DOI: 10.1016/j.tranon.2018.01.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
91 Prenek L, Boldizsár F, Kugyelka R, Ugor E, Berta G, Németh P, Berki T. The regulation of the mitochondrial apoptotic pathway by glucocorticoid receptor in collaboration with Bcl-2 family proteins in developing T cells. Apoptosis 2017;22:239-53. [PMID: 27888447 DOI: 10.1007/s10495-016-1320-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
92 von Pawel J, Spigel DR, Ervin T, Losonczy G, Barlesi F, Juhász E, Anderson M, McCall B, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Reck M. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. Oncologist 2018;23:654-e58. [PMID: 29438092 DOI: 10.1634/theoncologist.2017-0690] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
93 Ribatti D. Tumor refractoriness to anti-VEGF therapy. Oncotarget 2016;7:46668-77. [PMID: 27081695 DOI: 10.18632/oncotarget.8694] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 15.8] [Reference Citation Analysis]
94 Uhl CG, Muzykantov VR, Liu Y. Biomimetic microfluidic platform for the quantification of transient endothelial monolayer permeability and therapeutic transport under mimicked cancerous conditions. Biomicrofluidics 2018;12:014101. [PMID: 29333203 DOI: 10.1063/1.5000377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
95 Ribatti D. Anti-angiogenesis. Judah Folkman 2018. [DOI: 10.1007/978-3-319-92633-9_5] [Reference Citation Analysis]
96 Davis GE. Molecular Control of Capillary Tube Morphogenesis and Maturation Through Endothelial Cell-Pericyte Interactions: Regulation by Small GTPase-Mediated Signaling, Kinase Cascades, Extracellular Matrix Remodeling, and Defined Growth Factors. Biophysical Regulation of Vascular Differentiation and Assembly 2018. [DOI: 10.1007/978-3-319-99319-5_1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Dahan N, Magidey K, Shaked Y. Resistance to Inhibitors of Angiogenesis. Resistance to Targeted Anti-Cancer Therapeutics 2018. [DOI: 10.1007/978-3-319-67932-7_9] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
98 Ribatti D. Concluding Remarks. Judah Folkman 2018. [DOI: 10.1007/978-3-319-92633-9_6] [Reference Citation Analysis]
99 Sigalov AB. Targeting Intramembrane Protein-Protein Interactions: Novel Therapeutic Strategy of Millions Years Old. Adv Protein Chem Struct Biol 2018;111:61-99. [PMID: 29459036 DOI: 10.1016/bs.apcsb.2017.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
100 Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res 2017;23:7034-46. [PMID: 28855350 DOI: 10.1158/1078-0432.CCR-17-0647] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Breder VV, Laktionov KK, Davydov MI. PHARMACOLOGICAL THERAPY OF HEPATOCELLULAR CANCER PRACTICAL ISSUES AND SOLUTIONS. Medicinskij sovet 2017. [DOI: 10.21518/2079-701x-2017-14-11-23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
102 Vilanova G, Colominas I, Gomez H. A mathematical model of tumour angiogenesis: growth, regression and regrowth. J R Soc Interface 2017;14:20160918. [PMID: 28100829 DOI: 10.1098/rsif.2016.0918] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
103 Shimoyama S. Molecular Targeting Therapy for Gastric Cancer: Current Advances and Obstacles. Gastric Cancer 2017. [DOI: 10.5772/intechopen.69724] [Reference Citation Analysis]
104 Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res 2017;23:7034-46. [PMID: 28855350 DOI: 10.1158/1078-0432.CCR-17-0647] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
105 De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 2017;17:457-74. [DOI: 10.1038/nrc.2017.51] [Cited by in Crossref: 894] [Cited by in F6Publishing: 945] [Article Influence: 178.8] [Reference Citation Analysis]
106 Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini A, Torregrossa L, Basolo F, Vitti P, Elisei R. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol 2017;13:644-60. [PMID: 28707679 DOI: 10.1038/nrendo.2017.76] [Cited by in Crossref: 196] [Cited by in F6Publishing: 224] [Article Influence: 39.2] [Reference Citation Analysis]
107 Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM. Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. J Adv Res 2017;8:591-605. [PMID: 28808589 DOI: 10.1016/j.jare.2017.06.006] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 21.4] [Reference Citation Analysis]
108 Kondo M, Numata K, Hara K, Nozaki A, Fukuda H, Chuma M, Maeda S, Tanaka K. Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression. Gastroenterol Res Pract 2017;2017:5728946. [PMID: 28717362 DOI: 10.1155/2017/5728946] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
109 Zhang Y, Sun M, Huang G, Yin L, Lai Q, Yang Y, Xing X, Yu G, Sun Y, Wang X, Nie G, Liu Y, Cao Y. Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy. Proc Natl Acad Sci U S A 2017;114:E5226-35. [PMID: 28607065 DOI: 10.1073/pnas.1705066114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
110 Hovey EJ, Field KM, Rosenthal MA, Barnes EH, Cher L, Nowak AK, Wheeler H, Sawkins K, Livingstone A, Phal P, Goh C, Simes J; CABARET/COGNO investigators. Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial. Neurooncol Pract 2017;4:171-81. [PMID: 31386014 DOI: 10.1093/nop/npw025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
111 Talwar V, Pradeep Babu K, Raina S. An overall review of targeted therapy in solid cancers. Current Medicine Research and Practice 2017;7:99-105. [DOI: 10.1016/j.cmrp.2017.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
112 García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist 2017;22:375-e30. [PMID: 28275117 DOI: 10.1634/theoncologist.2016-0133] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
113 Schiffmann LM, Brunold M, Liwschitz M, Goede V, Loges S, Wroblewski M, Quaas A, Alakus H, Stippel D, Bruns CJ, Hallek M, Kashkar H, Hacker UT, Coutelle O. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer 2017;116:600-8. [PMID: 28141797 DOI: 10.1038/bjc.2017.13] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
114 Snoeren N, van Hillegersberg R, Schouten SB, Bergman AM, van Werkhoven E, Dalesio O, Tollenaar RA, Verheul HM, van der Sijp J, Borel Rinkes IH, Voest EE; Hepatica study group. Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study. Neoplasia 2017;19:93-9. [PMID: 28088688 DOI: 10.1016/j.neo.2016.08.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
115 Shi L, Cao HM, Li Y, Xu SX, Zhang Y, Zhang Y, Jin ZF. Electroacupuncture improves neurovascular unit reconstruction by promoting collateral circulation and angiogenesis. Neural Regen Res 2017;12:2000-6. [PMID: 29323038 DOI: 10.4103/1673-5374.221156] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
116 Jayson G, O’connor J. Imaging Tumor Angiogenesis. Tumor Angiogenesis 2017. [DOI: 10.1007/978-3-319-31215-6_7-1] [Reference Citation Analysis]
117 Tridente G. Pazopanib. Adverse Events and Oncotargeted Kinase Inhibitors 2017. [DOI: 10.1016/b978-0-12-809400-6.00013-5] [Reference Citation Analysis]
118 Jensen L, Cao Y. Angiogenesis: General Concepts. Angiogenesis-Based Dermatology 2017. [DOI: 10.1007/978-1-4471-7314-4_1] [Reference Citation Analysis]
119 Visvanathan A, Somasundaram K. Glioma Stem-Like Cells in Tumor Growth and Therapy Resistance of Glioblastoma. Advances in Biology and Treatment of Glioblastoma 2017. [DOI: 10.1007/978-3-319-56820-1_8] [Reference Citation Analysis]
120 Ribatti D. Anti-Angiogenic Cancer Therapy: Development of Resistance. Tumor Angiogenesis 2017. [DOI: 10.1007/978-3-319-31215-6_11-1] [Reference Citation Analysis]
121 Kragl M, Schubert R, Karsjens H, Otter S, Bartosinska B, Jeruschke K, Weiss J, Chen C, Alsteens D, Kuss O, Speier S, Eberhard D, Müller DJ, Lammert E. The biomechanical properties of an epithelial tissue determine the location of its vasculature. Nat Commun 2016;7:13560. [PMID: 27995929 DOI: 10.1038/ncomms13560] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
122 Bjarnason GA. Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients? Can Urol Assoc J 2016;10:S252-5. [PMID: 28096939 DOI: 10.5489/cuaj.4293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
123 Balaña C, Estival A, Pineda E, Sepúlveda J, Mesía C, Del Barco S, Gil-Gil M, Hardy M, Indacoechea A, Cardona AF. Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab. Neurooncol Pract 2017;4:15-23. [PMID: 31385992 DOI: 10.1093/nop/npw004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
124 Ferland-McCollough D, Slater S, Richard J, Reni C, Mangialardi G. Pericytes, an overlooked player in vascular pathobiology. Pharmacol Ther 2017;171:30-42. [PMID: 27916653 DOI: 10.1016/j.pharmthera.2016.11.008] [Cited by in Crossref: 111] [Cited by in F6Publishing: 118] [Article Influence: 18.5] [Reference Citation Analysis]
125 Gamucci T, Mentuccia L, Natoli C, Sperduti I, Cassano A, Michelotti A, Di Lauro L, Sergi D, Fabi A, Sarobba MG, Marchetti P, Barba M, Magnolfi E, Maugeri-Saccà M, Rossi E, Sini V, Grassadonia A, Pellegrini D, Astone A, Nisticò C, Angelini F, Vaccaro A, Pellegrino A, De Angelis C, Palleschi M, Moscetti L, Bertolini I, Buglioni S, Giordano A, Pizzuti L, Vici P. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. J Cell Physiol 2017;232:1571-8. [PMID: 27861874 DOI: 10.1002/jcp.25685] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
126 Pavana RK, Choudhary S, Bastian A, Ihnat MA, Bai R, Hamel E, Gangjee A. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. Bioorg Med Chem 2017;25:545-56. [PMID: 27894589 DOI: 10.1016/j.bmc.2016.11.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
127 Roviello G, Francini E, Perrella A, Laera L, Mazzei MA, Guerrini S, Petrioli R. An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer. Cancer Biol Ther 2015;16:1720-5. [PMID: 26418066 DOI: 10.1080/15384047.2015.1095410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
128 Shao R, Taylor SL, Oh DS, Schwartz LM. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget 2015;6:40507-18. [PMID: 26439689 DOI: 10.18632/oncotarget.5943] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
129 Nauta TD, van den Broek M, Gibbs S, van der Pouw-Kraan TC, Oudejans CB, van Hinsbergh VW, Koolwijk P. Identification of HIF-2α-regulated genes that play a role in human microvascular endothelial sprouting during prolonged hypoxia in vitro. Angiogenesis 2017;20:39-54. [PMID: 27699500 DOI: 10.1007/s10456-016-9527-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
130 Porta C, Chiellino S. ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. Ann Transl Med 2016;4:S14. [PMID: 27867982 DOI: 10.21037/atm.2016.10.45] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
131 Maj E, Papiernik D, Wietrzyk J. Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). Int J Oncol 2016;49:1773-84. [PMID: 27826619 DOI: 10.3892/ijo.2016.3709] [Cited by in Crossref: 86] [Cited by in F6Publishing: 93] [Article Influence: 14.3] [Reference Citation Analysis]
132 Narayanan S, Srinivas S. Incorporating VEGF-targeted therapy in advanced urothelial cancer. Ther Adv Med Oncol 2017;9:33-45. [PMID: 28203296 DOI: 10.1177/1758834016667179] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
133 Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960 [PMID: 27621761 DOI: 10.4254/wjh.v8.i23.957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
134 Nauta TD, Duyndam MC, Weijers EM, van Hinsbergh VM, Koolwijk P. HIF-2α Expression Regulates Sprout Formation into 3D Fibrin Matrices in Prolonged Hypoxia in Human Microvascular Endothelial Cells. PLoS One 2016;11:e0160700. [PMID: 27490118 DOI: 10.1371/journal.pone.0160700] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
135 Shi TT, Li G, Xiao HT. The Role of RhoJ in Endothelial Cell Biology and Tumor Pathology. Biomed Res Int 2016;2016:6386412. [PMID: 27556037 DOI: 10.1155/2016/6386412] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
136 Ponziani FR, Bhoori S, Germini A, Bongini M, Flores M, Sposito C, Facciorusso A, Gasbarrini A, Mazzaferro V. Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. Liver Int 2016;36:1033-42. [PMID: 26709844 DOI: 10.1111/liv.13052] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
137 Su JC, Mar AC, Wu SH, Tai WT, Chu PY, Wu CY, Tseng LM, Lee TC, Chen KF, Liu CY, Chiu HC, Shiau CW. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. Sci Rep 2016;6:28888. [PMID: 27364975 DOI: 10.1038/srep28888] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
138 Chappell JC, Cluceru JG, Nesmith JE, Mouillesseaux KP, Bradley VB, Hartland CM, Hashambhoy-Ramsay YL, Walpole J, Peirce SM, Mac Gabhann F, Bautch VL. Flt-1 (VEGFR-1) coordinates discrete stages of blood vessel formation. Cardiovasc Res 2016;111:84-93. [PMID: 27142980 DOI: 10.1093/cvr/cvw091] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
139 Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol 2016;13:611-26. [PMID: 27118493 DOI: 10.1038/nrclinonc.2016.57] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 14.3] [Reference Citation Analysis]
140 Pink A, Školnaja M, Päll T, Valkna A. CD44 Controls Endothelial Proliferation and Functions as Endogenous Inhibitor of Angiogenesis.. [DOI: 10.1101/049494] [Reference Citation Analysis]
141 Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 2016;126:1885-96. [PMID: 27064283 DOI: 10.1172/JCI85086] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 12.0] [Reference Citation Analysis]
142 Cao Y. Future options of anti-angiogenic cancer therapy. Chin J Cancer 2016;35:21. [PMID: 26879126 DOI: 10.1186/s40880-016-0084-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
143 Linville RM, Boland NF, Covarrubias G, Price GM, Tien J. Physical and Chemical Signals That Promote Vascularization of Capillary-Scale Channels. Cell Mol Bioeng 2016;9:73-84. [PMID: 27110295 DOI: 10.1007/s12195-016-0429-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
144 Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57-84. [PMID: 26753006 DOI: 10.1177/1758834015614530] [Cited by in Crossref: 263] [Cited by in F6Publishing: 287] [Article Influence: 43.8] [Reference Citation Analysis]
145 Ronellenfitsch U, Dimitrakopoulou-Strauss A, Jakob J, Kasper B, Nowak K, Pilz LR, Attenberger U, Gaiser T, Egerer G, Fröhling S, Derigs HG, Schwarzbach M, Hohenberger P. Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). BMJ Open 2016;6:e009558. [PMID: 26739732 DOI: 10.1136/bmjopen-2015-009558] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
146 Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 2016;35:4312-20. [PMID: 26725326 DOI: 10.1038/onc.2015.492] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 11.0] [Reference Citation Analysis]
147 Ribatti D. Tumor Angiogenesis. The Role of Microenvironment in the Control of Tumor Angiogenesis 2016. [DOI: 10.1007/978-3-319-27820-9_3] [Reference Citation Analysis]
148 Nasir A, Sheikh U, Muhammad J, Coppola D. Pathologic Angiogenesis in Neuroendocrine Tumors. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances 2016. [DOI: 10.1007/978-1-4939-3426-3_25] [Reference Citation Analysis]
149 He Z, Mitteer RA, Mou Y, Fan Y. Multimodality Targeting of Glioma Cells. Glioblastoma 2016. [DOI: 10.1016/b978-0-323-47660-7.00005-7] [Reference Citation Analysis]
150 Ribatti D. Tumor Blood Vessels and Tumor Endothelial Cells. The Role of Microenvironment in the Control of Tumor Angiogenesis 2016. [DOI: 10.1007/978-3-319-27820-9_2] [Reference Citation Analysis]
151 Liu J, Fan L, Wang H, Sun G. Autophagy, a double-edged sword in anti-angiogenesis therapy. Med Oncol 2016;33:10. [PMID: 26715036 DOI: 10.1007/s12032-015-0721-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
152 Mitsi M, Schulz MM, Gousopoulos E, Ochsenbein AM, Detmar M, Vogel V. Walking the Line: A Fibronectin Fiber-Guided Assay to Probe Early Steps of (Lymph)angiogenesis. PLoS One 2015;10:e0145210. [PMID: 26689200 DOI: 10.1371/journal.pone.0145210] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
153 Spenlé C, Saupe F, Midwood K, Burckel H, Noel G, Orend G. Tenascin-C: Exploitation and collateral damage in cancer management. Cell Adh Migr 2015;9:141-53. [PMID: 25569113 DOI: 10.1080/19336918.2014.1000074] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
154 Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomise H, Sakiyama S, Nishioka Y. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun 2015;6:8792. [PMID: 26635184 DOI: 10.1038/ncomms9792] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
155 Lee HS, Hos D, Blanco T, Bock F, Reyes NJ, Mathew R, Cursiefen C, Dana R, Saban DR. Involvement of corneal lymphangiogenesis in a mouse model of allergic eye disease. Invest Ophthalmol Vis Sci 2015;56:3140-8. [PMID: 26024097 DOI: 10.1167/iovs.14-16186] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
156 Zhao L, Li W, Zhang H, Hou N, Guo L, Gao Q. Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials. Onco Targets Ther 2015;8:2775-81. [PMID: 26491352 DOI: 10.2147/OTT.S88102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
157 Langlois B, Saupe F, Rupp T, Arnold C, van der Heyden M, Orend G, Hussenet T. AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients. Oncotarget 2014;5:10529-45. [PMID: 25301723 DOI: 10.18632/oncotarget.2470] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
158 Tabouret T, Gregory T, Dhooge M, Brezault C, Mir O, Dréanic J, Chaussade S, Coriat R. Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis. Invest New Drugs 2015;33:1144-7. [PMID: 26311072 DOI: 10.1007/s10637-015-0283-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
159 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 117] [Cited by in F6Publishing: 124] [Article Influence: 16.7] [Reference Citation Analysis]
160 Davis GE, Norden PR, Bowers SL. Molecular control of capillary morphogenesis and maturation by recognition and remodeling of the extracellular matrix: functional roles of endothelial cells and pericytes in health and disease. Connect Tissue Res 2015;56:392-402. [PMID: 26305158 DOI: 10.3109/03008207.2015.1066781] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
161 Pollom EL, Deng L, Pai RK, Brown JM, Giaccia A, Loo BW Jr, Shultz DB, Le QT, Koong AC, Chang DT. Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2015;92:568-76. [PMID: 26068491 DOI: 10.1016/j.ijrobp.2015.02.016] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
162 Hod T, Cerdeira AS, Karumanchi SA. Molecular Mechanisms of Preeclampsia. Cold Spring Harb Perspect Med 2015;5:a023473. [PMID: 26292986 DOI: 10.1101/cshperspect.a023473] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 13.9] [Reference Citation Analysis]
163 Miao L, Huang L. Exploring the tumor microenvironment with nanoparticles. Cancer Treat Res 2015;166:193-226. [PMID: 25895870 DOI: 10.1007/978-3-319-16555-4_9] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 10.6] [Reference Citation Analysis]
164 Janota C, Lemere CA, Brito MA. Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer's Disease. Mol Neurobiol 2016;53:3793-811. [PMID: 26143259 DOI: 10.1007/s12035-015-9319-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
165 Khattab MH, Marciscano AE, Lo SS, Lim M, Laterra JJ, Kleinberg LR, Redmond KJ. Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature. Case Rep Oncol Med 2015;2015:431819. [PMID: 26199775 DOI: 10.1155/2015/431819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
166 Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Vet Res 2015;11:131. [PMID: 26062540 DOI: 10.1186/s12917-015-0446-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
167 Gacche RN. Compensatory angiogenesis and tumor refractoriness. Oncogenesis 2015;4:e153. [PMID: 26029827 DOI: 10.1038/oncsis.2015.14] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 9.7] [Reference Citation Analysis]
168 Zhao Y, Adjei AA. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist 2015;20:660-73. [PMID: 26001391 DOI: 10.1634/theoncologist.2014-0465] [Cited by in Crossref: 326] [Cited by in F6Publishing: 346] [Article Influence: 46.6] [Reference Citation Analysis]
169 Otsuka T, Nakashita S, Yanagita K, Ario K, Kawasoe H, Kawazoe S, Eguchi Y, Mizuta T. Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Diseases 2015;3:68-77. [PMID: 28943609 DOI: 10.3390/diseases3020068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
170 Flanigan PM, Aghi MK. Adaptation to antiangiogenic therapy in neurological tumors. Cell Mol Life Sci 2015;72:3069-82. [PMID: 25943307 DOI: 10.1007/s00018-015-1916-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
171 Ribeiro AL, Okamoto OK. Combined effects of pericytes in the tumor microenvironment. Stem Cells Int 2015;2015:868475. [PMID: 26000022 DOI: 10.1155/2015/868475] [Cited by in Crossref: 91] [Cited by in F6Publishing: 99] [Article Influence: 13.0] [Reference Citation Analysis]
172 Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol. 2015;44-46:94-112. [PMID: 25912949 DOI: 10.1016/j.matbio.2015.04.004] [Cited by in Crossref: 236] [Cited by in F6Publishing: 259] [Article Influence: 33.7] [Reference Citation Analysis]
173 Boland NF, Linville RM, Covarrubias G, Tien J. Vascularization of capillary-scale channels in type I collagen gels. 2015 41st Annual Northeast Biomedical Engineering Conference (NEBEC) 2015. [DOI: 10.1109/nebec.2015.7117067] [Reference Citation Analysis]
174 Roviello G, Francini E, Perrella A, Laera L, Mazzei MA, Guerrini S, Roviello F, Marrelli D, Petrioli R. Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. Cancer Biol Ther 2015;16:493-7. [PMID: 25719413 DOI: 10.1080/15384047.2015.1017692] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
175 Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Matsumoto K, Yonekura K, Yano S. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol 2014;9:775-83. [PMID: 24828661 DOI: 10.1097/JTO.0000000000000170] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
176 Massari F, Ciccarese C, Bimbatti D, Fantinel E, Modena A, Simbolo M, Brunelli M, Artibani W, Martignoni G, Scarpa A, Tortora G. Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy. Anticancer Drugs 2015;26:469-73. [PMID: 25569703 DOI: 10.1097/CAD.0000000000000208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
177 Coutelle O, Schiffmann LM, Liwschitz M, Brunold M, Goede V, Hallek M, Kashkar H, Hacker UT. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours. Br J Cancer 2015;112:495-503. [PMID: 25562438 DOI: 10.1038/bjc.2014.629] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
178 Escudier B, Albiges L. Anti-VEGF and VEGFR Monoclonal Antibodies in RCC. Renal Cell Carcinoma 2015. [DOI: 10.1007/978-1-4939-1622-1_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 Yokoi T, Kurata T, Torii Y, Katashiba Y, Ogata M, Satsutani NM, Niki M, Katashiba NI, Kibata KN, Nomura S. Efficacy and Safety of Continuing Bevacizumab beyond Disease Progression plus Docetaxel in Patients with Non-Small Cell Lung Cancer: A Retrospective Analysis. ALC 2015;04:8-15. [DOI: 10.4236/alc.2015.41002] [Reference Citation Analysis]
180 Hicks MJ, Funato K, Wang L, Aronowitz E, Dyke JP, Ballon DJ, Havlicek DF, Frenk EZ, De BP, Chiuchiolo MJ, Sondhi D, Hackett NR, Kaminsky SM, Tabar V, Crystal RG. Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Ther 2015;22:1-8. [PMID: 25501993 DOI: 10.1038/cgt.2014.58] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
181 Raymond E, Faivre S. Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours. Curr Oncol. 2014;21:309-317. [PMID: 25489258 DOI: 10.3747/co.21.1647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
182 Kainuma S, Miyagawa S, Fukushima S, Pearson J, Chen YC, Saito A, Harada A, Shiozaki M, Iseoka H, Watabe T, Watabe H, Horitsugi G, Ishibashi M, Ikeda H, Tsuchimochi H, Sonobe T, Fujii Y, Naito H, Umetani K, Shimizu T, Okano T, Kobayashi E, Daimon T, Ueno T, Kuratani T, Toda K, Takakura N, Hatazawa J, Shirai M, Sawa Y. Cell-sheet therapy with omentopexy promotes arteriogenesis and improves coronary circulation physiology in failing heart. Mol Ther 2015;23:374-86. [PMID: 25421595 DOI: 10.1038/mt.2014.225] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
183 Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 2015;14:101-10. [PMID: 25381264 DOI: 10.1158/1535-7163.MCT-14-0094] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 8.4] [Reference Citation Analysis]
184 Nauta TD, van Hinsbergh VW, Koolwijk P. Hypoxic signaling during tissue repair and regenerative medicine. Int J Mol Sci. 2014;15:19791-19815. [PMID: 25365172 DOI: 10.3390/ijms151119791] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 8.3] [Reference Citation Analysis]
185 Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 2014;111:1909-16. [PMID: 25349968 DOI: 10.1038/bjc.2014.503] [Cited by in Crossref: 122] [Cited by in F6Publishing: 132] [Article Influence: 15.3] [Reference Citation Analysis]
186 Kano MR. Nanotechnology and tumor microcirculation. Adv Drug Deliv Rev 2014;74:2-11. [PMID: 23994441 DOI: 10.1016/j.addr.2013.08.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
187 Doloff JC, Chen CS, Waxman DJ. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Mol Cancer 2014;13:158. [PMID: 24965046 DOI: 10.1186/1476-4598-13-158] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
188 Peng Y, Guo JJ, Liu YM, Wu XL. MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci Rep. 2014;34. [PMID: 24837198 DOI: 10.1042/bsr20140020] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 8.6] [Reference Citation Analysis]
189 Liapi E, Geschwind JF. Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma. Liver Cancer. 2012;1:201-215. [PMID: 24159585 DOI: 10.1159/000343835] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
190 Zhao XY, Yang S, Chen YR, Li PC, Dou MM, Zhang J. Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo. PLoS One 2014;9:e98925. [PMID: 24901647 DOI: 10.1371/journal.pone.0098925] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
191 Marinelli S, Salvatore V, Baron Toaldo M, Milazzo M, Croci L, Venerandi L, Pecorelli A, Palamà C, Diana A, Bolondi L, Piscaglia F. Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma. BMC Cancer 2014;14:403. [PMID: 24902850 DOI: 10.1186/1471-2407-14-403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
192 Kaulfuß S, Seemann H, Kampe R, Meyer J, Dressel R, König B, Scharf JG, Burfeind P. Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells. Oncotarget 2013;4:1037-49. [PMID: 23900414 DOI: 10.18632/oncotarget.1085] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
193 D'Alessandro R, Refolo MG, Lippolis C, Messa C, Cavallini A, Rossi R, Resta L, Di Carlo A, Carr BI. Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol 2013;72:869-77. [PMID: 23959464 DOI: 10.1007/s00280-013-2269-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
194 Patel SR, Karnad AB, Ketchum NS, Pollock BH, Sarantopoulos J, Weitman S, Mahalingam D. Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. J Gastrointest Oncol 2014;5:99-103. [PMID: 24772337 DOI: 10.3978/j.issn.2078-6891.2014.002] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
195 Wicki A, Wild D, Prêtre V, Mansi R, Orleth A, Reubi JC, Rochlitz C, Mamot C, Mäcke HR, Christofori G. Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors. EJNMMI Res 2014;4:9. [PMID: 24528513 DOI: 10.1186/2191-219X-4-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
196 Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471-94. [PMID: 24482243 DOI: 10.1007/s10456-014-9420-y] [Cited by in Crossref: 474] [Cited by in F6Publishing: 430] [Article Influence: 59.3] [Reference Citation Analysis]
197 Talaber G, Miklossy G, Oaks Z, Liu Y, Tooze SA, Chudakov DM, Banki K, Perl A. HRES-1/Rab4 promotes the formation of LC3(+) autophagosomes and the accumulation of mitochondria during autophagy. PLoS One 2014;9:e84392. [PMID: 24404161 DOI: 10.1371/journal.pone.0084392] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
198 Nahleh ZA. Overview of Metronomic Chemotherapy in SWOG Breast Cancer Cooperative Group Clinical Trials. Metronomic Chemotherapy 2014. [DOI: 10.1007/978-3-662-43604-2_7] [Reference Citation Analysis]
199 Harris AL, Generali D. Inhibitors of Tumor Angiogenesis. Cancer Drug Design and Discovery 2014. [DOI: 10.1016/b978-0-12-396521-9.00010-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
200 Teulé A, Martín L, Casanovas O. Relevance of Angiogenesis in Neuroendocrine Tumors. Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract 2014. [DOI: 10.1007/978-2-8178-0430-9_3] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
201 Eveno C, Pocard M. Anti-angiogenic Therapies in Colorectal Cancer. Molecular Mechanisms of Angiogenesis 2014. [DOI: 10.1007/978-2-8178-0466-8_19] [Reference Citation Analysis]
202 Grépin R, Guyot M, Pagès G. Resistance to Antiangiogenic Treatments via Upregulation of Substitution Pathways. Molecular Mechanisms of Angiogenesis 2014. [DOI: 10.1007/978-2-8178-0466-8_20] [Reference Citation Analysis]
203 Stapor PC, De Bock K, Carmeliet P. Essentials of Angiogenesis. PanVascular Medicine 2014. [DOI: 10.1007/978-3-642-37393-0_10-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
204 Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci USA. 2013;110:18632-18637. [PMID: 24167277 DOI: 10.1073/pnas.1318415110] [Cited by in Crossref: 279] [Cited by in F6Publishing: 292] [Article Influence: 31.0] [Reference Citation Analysis]
205 Fan Y, Huang Z, Mao W. Bevacizumab treatment for advanced non-small cell lung cancer: A case report. Oncol Lett 2013;6:1779-83. [PMID: 24260075 DOI: 10.3892/ol.2013.1603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
206 Langlet F, Levin BE, Luquet S, Mazzone M, Messina A, Dunn-Meynell AA, Balland E, Lacombe A, Mazur D, Carmeliet P, Bouret SG, Prevot V, Dehouck B. Tanycytic VEGF-A boosts blood-hypothalamus barrier plasticity and access of metabolic signals to the arcuate nucleus in response to fasting. Cell Metab 2013;17:607-17. [PMID: 23562080 DOI: 10.1016/j.cmet.2013.03.004] [Cited by in Crossref: 238] [Cited by in F6Publishing: 199] [Article Influence: 26.4] [Reference Citation Analysis]
207 Wei K, Piecewicz SM, McGinnis LM, Taniguchi CM, Wiegand SJ, Anderson K, Chan CW, Mulligan KX, Kuo D, Yuan J, Vallon M, Morton L, Lefai E, Simon MC, Maher JJ, Mithieux G, Rajas F, Annes J, McGuinness OP, Thurston G, Giaccia AJ, Kuo CJ. A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nat Med 2013;19:1331-7. [PMID: 24037094 DOI: 10.1038/nm.3295] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 9.2] [Reference Citation Analysis]
208 Nelson VM, Benson AB 3rd. Status of targeted therapies in the adjuvant treatment of colon cancer. J Gastrointest Oncol 2013;4:245-52. [PMID: 23997937 DOI: 10.3978/j.issn.2078-6891.2013.035] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
209 Hah YS, Koh YJ, Lim HS, Kim HO, Cheon YH, Noh HS, Jang KY, Lee SY, Lee GM, Koh GY, Lee SI. Double-antiangiogenic protein DAAP targeting vascular endothelial growth factor A and angiopoietins attenuates collagen-induced arthritis. Arthritis Res Ther 2013;15:R85. [PMID: 23945080 DOI: 10.1186/ar4265] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
210 Vasudev NS, Goh V, Juttla JK, Thompson VL, Larkin JM, Gore M, Nathan PD, Reynolds AR. Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. Br J Cancer 2013;109:1230-42. [PMID: 23922108 DOI: 10.1038/bjc.2013.429] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
211 Yang X, Zhang Y, Yang Y, Lim S, Cao Z, Rak J, Cao Y. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci U S A 2013;110:13932-7. [PMID: 23918367 DOI: 10.1073/pnas.1309629110] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.8] [Reference Citation Analysis]
212 Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123:3190-3200. [PMID: 23908119 DOI: 10.1172/jci70212] [Cited by in Crossref: 442] [Cited by in F6Publishing: 460] [Article Influence: 49.1] [Reference Citation Analysis]
213 Yang Y, Zhang Y, Cao Z, Ji H, Yang X, Iwamoto H, Wahlberg E, Länne T, Sun B, Cao Y. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U S A. 2013;110:12018-12023. [PMID: 23818623 DOI: 10.1073/pnas.1301331110] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 10.6] [Reference Citation Analysis]
214 Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D. Hypoxia, notch signalling, and prostate cancer. Nat Rev Urol 2013;10:405-13. [PMID: 23712204 DOI: 10.1038/nrurol.2013.110] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
215 Kelly-Goss MR, Sweat RS, Azimi MS, Murfee WL. Vascular islands during microvascular regression and regrowth in adult networks. Front Physiol 2013;4:108. [PMID: 23720632 DOI: 10.3389/fphys.2013.00108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
216 Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012;32:1095-111. [PMID: 23208836 DOI: 10.1002/phar.1147] [Cited by in Crossref: 132] [Cited by in F6Publishing: 140] [Article Influence: 14.7] [Reference Citation Analysis]
217 Weinl C, Riehle H, Park D, Stritt C, Beck S, Huber G, Wolburg H, Olson EN, Seeliger MW, Adams RH, Nordheim A. Endothelial SRF/MRTF ablation causes vascular disease phenotypes in murine retinae. J Clin Invest 2013;123:2193-206. [PMID: 23563308 DOI: 10.1172/JCI64201] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
218 Williamson SC, Hartley AE, Heer R. A review of tasquinimod in the treatment of advanced prostate cancer. Drug Des Devel Ther 2013;7:167-74. [PMID: 23662046 DOI: 10.2147/DDDT.S31500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
219 Eklund L, Bry M, Alitalo K. Mouse models for studying angiogenesis and lymphangiogenesis in cancer. Mol Oncol 2013;7:259-82. [PMID: 23522958 DOI: 10.1016/j.molonc.2013.02.007] [Cited by in Crossref: 85] [Cited by in F6Publishing: 93] [Article Influence: 9.4] [Reference Citation Analysis]
220 Xue H, Zhou S, Lu W, Zhao Z. [The targets research of non-small cell lung cancer targeted therapy]. Zhongguo Fei Ai Za Zhi 2013;16:107-13. [PMID: 23425904 DOI: 10.3779/j.issn.1009-3419.2013.02.09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Awazu Y, Mizutani A, Nagase Y, Tsuchiya S, Nakamura K, Kakoi Y, Kitahara O, Takeuchi T, Yamasaki S, Miyamoto N, Iwata H, Miki H, Imamura S, Hori A. Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase. Cancer Sci 2013;104:486-94. [PMID: 23305239 DOI: 10.1111/cas.12101] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
222 Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. Invest New Drugs. 2013;31:1035-1043. [PMID: 23417697 DOI: 10.1007/s10637-013-9936-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
223 Gordon LK, Kiyohara M, Fu M, Braun J, Dhawan P, Chan A, Goodglick L, Wadehra M. EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF. Oncogene 2013;32:5369-76. [PMID: 23334331 DOI: 10.1038/onc.2012.622] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
224 Lynn KD, Brekken RA. Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer? Cancer Discov. 2012;2:211-213. [PMID: 22585992 DOI: 10.1158/2159-8290.cd-12-0037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
225 Thiriet M. Vasculature Growth. Tissue Functioning and Remodeling in the Circulatory and Ventilatory Systems 2013. [DOI: 10.1007/978-1-4614-5966-8_10] [Reference Citation Analysis]
226 Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012;12:699-709. [PMID: 23001349 DOI: 10.1038/nrc3366] [Cited by in Crossref: 189] [Cited by in F6Publishing: 200] [Article Influence: 18.9] [Reference Citation Analysis]
227 Wada Y, Tanoue K, Takahashi W, Eto M. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. Transl Androl Urol 2012;1:204-6. [PMID: 26816712 DOI: 10.3978/j.issn.2223-4683.2012.05.04] [Reference Citation Analysis]
228 Manley E Jr, Waxman DJ. Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone. J Pharmacol Exp Ther 2013;344:368-77. [PMID: 23192656 DOI: 10.1124/jpet.112.200089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
229 Lohmann AE, Chia S. Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it? Curr Treat Options Oncol 2012;13:249-62. [PMID: 22350496 DOI: 10.1007/s11864-012-0181-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
230 Sawada J, Urakami T, Li F, Urakami A, Zhu W, Fukuda M, Li DY, Ruoslahti E, Komatsu M. Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell. 2012;22:235-249. [PMID: 22897853 DOI: 10.1016/j.ccr.2012.06.013] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
231 Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer 2012;12:482. [PMID: 23083011 DOI: 10.1186/1471-2407-12-482] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
232 Männistö T, Karumanchi SA, Pouta A, Vääräsmäki M, Mendola P, Miettola S, Surcel HM, Bloigu A, Ruokonen A, Järvelin MR, Hartikainen AL, Suvanto E. Preeclampsia, gestational hypertension and subsequent hypothyroidism. Pregnancy Hypertens 2013;3:21-7. [PMID: 23439671 DOI: 10.1016/j.preghy.2012.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
233 Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst. 2012;104:1320-1334. [PMID: 22911669 DOI: 10.1093/jnci/djs336] [Cited by in Crossref: 126] [Cited by in F6Publishing: 135] [Article Influence: 12.6] [Reference Citation Analysis]
234 Perez CA, Arango BA, Velez M, Raez LE, Santos ES. Emerging role of multikinase inhibitors for refractory thyroid cancer. Biologics 2012;6:257-65. [PMID: 22904617 DOI: 10.2147/BTT.S24465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
235 Takeda M, Okamoto I, Yamanaka T, Nakagawa K, Nakanishi Y. Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L). BMC Cancer 2012;12:327. [PMID: 22849580 DOI: 10.1186/1471-2407-12-327] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
236 Reddy S, Raffin M, Kaklamani V. Targeting angiogenesis in metastatic breast cancer. Oncologist 2012;17:1014-26. [PMID: 22843553 DOI: 10.1634/theoncologist.2012-0043] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
237 Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 2012;14:564-74. [PMID: 22855137 DOI: 10.1007/s12094-012-0842-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
238 Trinh XB, van Dam PA, Vermeulen PB, Van Laere SJ, Van den Eynden GG, Tjalma WA, Dirix LY. VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer. Clin Transl Oncol 2011;13:805-8. [PMID: 22082645 DOI: 10.1007/s12094-011-0737-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
239 Taccaliti A, Silvetti F, Palmonella G, Boscaro M. Anaplastic thyroid carcinoma. Front Endocrinol (Lausanne) 2012;3:84. [PMID: 22783225 DOI: 10.3389/fendo.2012.00084] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
240 Schmidt B, Lee HJ, Ryeom S, Yoon SS. Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials. Curr Angiogenes 2012;1:169-79. [PMID: 24977113 DOI: 10.2174/2211552811201030169] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
241 Rojas A, Chang FC, Lin SL, Duffield JS. The role played by perivascular cells in kidney interstitial injury. Clin Nephrol 2012;77:400-8. [PMID: 22551886 DOI: 10.5414/cn107371] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
242 Kim YJ, Lee HJ, Kim TM, Eisinger-Mathason TS, Zhang AY, Schmidt B, Karl DL, Nakazawa MS, Park PJ, Simon MC, Yoon SS. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α. Int J Cancer 2013;132:29-41. [PMID: 22684860 DOI: 10.1002/ijc.27666] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
243 van Geel RM, Beijnen JH, Schellens JH. Concise drug review: pazopanib and axitinib. Oncologist 2012;17:1081-9. [PMID: 22733795 DOI: 10.1634/theoncologist.2012-0055] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
244 Grünwald V, Merseburger AS. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. Onco Targets Ther 2012;5:111-7. [PMID: 22787405 DOI: 10.2147/OTT.S23273] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
245 Deryugina E. Experimental Approaches for Understanding the Role of Matrix Metalloproteinases in Cancer Invasion. Matrix Proteases in Health and Disease 2012. [DOI: 10.1002/9783527649327.ch8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
246 Nakao S, Zandi S, Lara-Castillo N, Taher M, Ishibashi T, Hafezi-Moghadam A. Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis: surprisingly similar impact on leukocyte infiltration. Invest Ophthalmol Vis Sci 2012;53:3296-302. [PMID: 22427602 DOI: 10.1167/iovs.11-8114] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
247 Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012;72:1909-1914. [PMID: 22508695 DOI: 10.1158/0008-5472.can-11-3406] [Cited by in Crossref: 260] [Cited by in F6Publishing: 275] [Article Influence: 26.0] [Reference Citation Analysis]
248 Francescone R, Scully S, Bentley B, Yan W, Taylor SL, Oh D, Moral L, Shao R. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem 2012;287:24821-31. [PMID: 22654102 DOI: 10.1074/jbc.M111.334540] [Cited by in Crossref: 107] [Cited by in F6Publishing: 112] [Article Influence: 10.7] [Reference Citation Analysis]
249 Barr S, Falcon BL, Ghokale PC, Chou J, Fogarty J, Depeille P, Miglarese M, Epstein DM. Abstract B1: Dual mTORC1/mTORC2 inhibition limits tumor growth, VEGF production and vascular regrowth. Clinical Cancer Research 2012;18:B1-B1. [DOI: 10.1158/1078-0432.mechres-b1] [Reference Citation Analysis]
250 Suzuki Y, Saeki T, Aogi K, Toi M, Fujii H, Inoue K, Watanabe T, Fujiwara Y, Ito Y, Takatsuka Y, Iwata H, Arioka H, Tokuda Y. A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. Int J Clin Oncol 2013;18:590-7. [PMID: 22585426 DOI: 10.1007/s10147-012-0421-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
251 Griffioen AW, Mans LA, de Graaf AMA, Nowak-Sliwinska P, de Hoog CLMM, de Jong TAM, Vyth-Dreese FA, van Beijnum JR, Bex A, Jonasch E. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012;18:3961-71. [PMID: 22573349 DOI: 10.1158/1078-0432.CCR-12-0002] [Cited by in Crossref: 118] [Cited by in F6Publishing: 122] [Article Influence: 11.8] [Reference Citation Analysis]
252 Ding Y, Song N, Luo Y. Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes. Cancer Microenviron 2012;5:225-36. [PMID: 22528877 DOI: 10.1007/s12307-012-0106-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
253 Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, Kerbel R, Klagsbrun M, Lim S, Moses MA, Zetter B, Dvorak H, Langer R. Forty-year journey of angiogenesis translational research. Sci Transl Med 2011;3:114rv3. [PMID: 22190240 DOI: 10.1126/scitranslmed.3003149] [Cited by in Crossref: 108] [Cited by in F6Publishing: 147] [Article Influence: 10.8] [Reference Citation Analysis]
254 Sirsi SR, Flexman ML, Vlachos F, Huang J, Hernandez SL, Kim HK, Johung TB, Gander JW, Reichstein AR, Lampl BS, Wang A, Hielscher AH, Kandel JJ, Yamashiro DJ, Borden MA. Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. Ultrasound Med Biol 2012;38:1019-29. [PMID: 22425376 DOI: 10.1016/j.ultrasmedbio.2012.01.014] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
255 Dienstmann R, Ades F, Saini KS, Metzger-Filho O. Benefit-risk assessment of bevacizumab in the treatment of breast cancer. Drug Saf 2012;35:15-25. [PMID: 22136182 DOI: 10.2165/11595910-000000000-00000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
256 Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 2012;3:21. [PMID: 22566905 DOI: 10.3389/fimmu.2012.00021] [Cited by in Crossref: 116] [Cited by in F6Publishing: 127] [Article Influence: 11.6] [Reference Citation Analysis]
257 Jin K, Lan H, Cao F, Xu Z, Han N, Li G, He K, Teng L. Antitumor effect of FP3 in a patient-derived tumor tissue xenograft model of gastric carcinoma through an antiangiogenic mechanism. Oncol Lett 2012;3:1052-8. [PMID: 22783390 DOI: 10.3892/ol.2012.603] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
258 Montecinos VP, Godoy A, Hinklin J, Vethanayagam RR, Smith GJ. Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma. PLoS One 2012;7:e29623. [PMID: 22303438 DOI: 10.1371/journal.pone.0029623] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
259 Chen DS. Anti-Angiogenesis Therapy in Melanoma. Targeted Therapeutics in Melanoma 2012. [DOI: 10.1007/978-1-61779-407-0_10] [Reference Citation Analysis]
260 Metro G, Crinò L. Targeted Therapies for Non-small-Cell Lung Cancer. Biotargets of Cancer in Current Clinical Practice 2012. [DOI: 10.1007/978-1-61779-615-9_4] [Reference Citation Analysis]
261 Naito H, Takara K, Wakabayashi T, Kawahara H, Kidoya H, Takakura N. Changes in blood vessel maturation in the fibrous cap of the tumor rim. Cancer Sci 2012;103:433-8. [PMID: 22098620 DOI: 10.1111/j.1349-7006.2011.02157.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
262 Jin K, Li G, Cui B, Zhang J, Lan H, Han N, Xie B, Cao F, He K, Wang H, Xu Z, Teng L, Zhu T. Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS One 2011;6:e28384. [PMID: 22164281 DOI: 10.1371/journal.pone.0028384] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
263 Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010;1:12-25. [PMID: 21779425 DOI: 10.1177/1947601909356574] [Cited by in Crossref: 196] [Cited by in F6Publishing: 208] [Article Influence: 17.8] [Reference Citation Analysis]
264 Harris LG, Pannell LK, Singh S, Samant RS, Shevde LA. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61. Oncogene 2012;31:3370-80. [PMID: 22056874 DOI: 10.1038/onc.2011.496] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 7.5] [Reference Citation Analysis]
265 Chappell JC, Wiley DM, Bautch VL. Regulation of blood vessel sprouting. Semin Cell Dev Biol 2011;22:1005-11. [PMID: 22020130 DOI: 10.1016/j.semcdb.2011.10.006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
266 Murakami M, Nguyen LT, Hatanaka K, Schachterle W, Chen PY, Zhuang ZW, Black BL, Simons M. FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest 2011;121:2668-78. [PMID: 21633168 DOI: 10.1172/JCI44762] [Cited by in Crossref: 124] [Cited by in F6Publishing: 131] [Article Influence: 11.3] [Reference Citation Analysis]
267 Kesselheim JC, Norden AD, Wen PY, Joffe S. Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis. Oncologist 2011;16:1435-9. [PMID: 21948651 DOI: 10.1634/theoncologist.2011-0047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
268 Senger DR, Davis GE. Angiogenesis. Cold Spring Harb Perspect Biol 2011;3:a005090. [PMID: 21807843 DOI: 10.1101/cshperspect.a005090] [Cited by in Crossref: 213] [Cited by in F6Publishing: 224] [Article Influence: 19.4] [Reference Citation Analysis]
269 Blankenberg FG, Levashova Z, Sarkar SK, Pizzonia J, Backer MV, Backer JM. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol 2010;3:56-64. [PMID: 20165696 DOI: 10.1593/tlo.09271] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
270 Escudier B, Cosaert J, Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics 2008;2:517-30. [PMID: 19707382 DOI: 10.2147/btt.s3509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
271 Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298-307. [PMID: 21593862 DOI: 10.1038/nature10144] [Cited by in Crossref: 3471] [Cited by in F6Publishing: 3635] [Article Influence: 315.5] [Reference Citation Analysis]
272 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/thenocoligist.2010-0387] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
273 De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol. 2011;8:393-404. [PMID: 21629216 DOI: 10.1038/nrclinonc.2011.83] [Cited by in Crossref: 208] [Cited by in F6Publishing: 219] [Article Influence: 18.9] [Reference Citation Analysis]
274 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/theoncologist.2010-0387] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
275 You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011;71:4758-68. [PMID: 21613405 DOI: 10.1158/0008-5472.CAN-10-2527] [Cited by in Crossref: 178] [Cited by in F6Publishing: 192] [Article Influence: 16.2] [Reference Citation Analysis]
276 Flister MJ, Volk LD, Ran S. Characterization of Prox1 and VEGFR-3 expression and lymphatic phenotype in normal organs of mice lacking p50 subunit of NF-κB. Microcirculation 2011;18:85-101. [PMID: 21166921 DOI: 10.1111/j.1549-8719.2010.00057.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
277 Di Salvatore M, Orlandi A, Bagalà C, Quirino M, Cassano A, Astone A, Barone C. Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 2011;44:139-46. [PMID: 21401755 DOI: 10.1111/j.1365-2184.2011.00745.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
278 Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol 2011;37:56-74. [PMID: 20946471 DOI: 10.1111/j.1365-2990.2010.01139.x] [Cited by in Crossref: 477] [Cited by in F6Publishing: 508] [Article Influence: 43.4] [Reference Citation Analysis]
279 Jubb AM, Cesario A, Ferguson M, Congedo MT, Gatter KC, Lococo F, Mulè A, Pezzella F. Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer 2011;104:1877-81. [PMID: 21540863 DOI: 10.1038/bjc.2011.147] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
280 Marijon H, Dokmak S, Paradis V, Zappa M, Bieche I, Bouattour M, Raymond E, Faivre S. Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol 2011;54:1073-8. [PMID: 21145871 DOI: 10.1016/j.jhep.2010.11.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
281 Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, Miglarese M, Epstein DM, McDonald DM. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res 2011;71:1573-83. [PMID: 21363918 DOI: 10.1158/0008-5472.CAN-10-3126] [Cited by in Crossref: 73] [Cited by in F6Publishing: 78] [Article Influence: 6.6] [Reference Citation Analysis]
282 Bhattacharya A. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opin Drug Deliv 2011;8:749-63. [PMID: 21473705 DOI: 10.1517/17425247.2011.571672] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
283 Buckstein R, Kuruvilla J, Chua N, Lee C, Macdonald DA, Al-Tourah AJ, Foo AH, Walsh W, Ivy SP, Crump M, Eisenhauer EA. Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leuk Lymphoma 2011;52:833-41. [PMID: 21463120 DOI: 10.3109/10428194.2011.555892] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
284 Ma J, Chen CS, Blute T, Waxman DJ. Antiangiogenesis enhances intratumoral drug retention. Cancer Res. 2011;71:2675-2685. [PMID: 21447737 DOI: 10.1158/0008-5472.can-10-3242] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
285 Perri F, Lorenzo GD, Scarpati GDV, Buonerba C. Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol 2011; 2(3): 150-157 [PMID: 21611089 DOI: 10.5306/wjco.v2.i3.150] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 74] [Article Influence: 5.7] [Reference Citation Analysis]
286 Kerr DJ, Young AM. Targeted therapies: bevacizumab--has it reached its final resting place? Nat Rev Clin Oncol 2011;8:195-6. [PMID: 21386819 DOI: 10.1038/nrclinonc.2011.32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
287 Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21. [PMID: 21364524 DOI: 10.1038/nrclinonc.2011.21] [Cited by in Crossref: 513] [Cited by in F6Publishing: 546] [Article Influence: 46.6] [Reference Citation Analysis]
288 Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 2011;10:742-51. [PMID: 21357475 DOI: 10.1158/1535-7163.MCT-10-0868] [Cited by in Crossref: 110] [Cited by in F6Publishing: 125] [Article Influence: 10.0] [Reference Citation Analysis]
289 di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 2011;71:19-28. [PMID: 21199795 DOI: 10.1158/0008-5472.CAN-10-2602] [Cited by in Crossref: 150] [Cited by in F6Publishing: 160] [Article Influence: 13.6] [Reference Citation Analysis]
290 Ni A, Lashnits E, Yao LC, Baluk P, McDonald DM. Rapid remodeling of airway vascular architecture at birth. Dev Dyn 2010;239:2354-66. [PMID: 20730909 DOI: 10.1002/dvdy.22379] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
291 Brown WR. A review of string vessels or collapsed, empty basement membrane tubes. J Alzheimers Dis 2010;21:725-39. [PMID: 20634580 DOI: 10.3233/JAD-2010-100219] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 6.5] [Reference Citation Analysis]
292 Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 2011;29:1014-21. [PMID: 21220618 DOI: 10.1200/JCO.2009.27.6543] [Cited by in Crossref: 46] [Cited by in F6Publishing: 60] [Article Influence: 4.2] [Reference Citation Analysis]
293 Davis GE, Stratman AN, Sacharidou A. Molecular Control of Vascular Tube Morphogenesis and Stabilization: Regulation by Extracellular Matrix, Matrix Metalloproteinases, and Endothelial Cell–Pericyte Interactions. Biophysical Regulation of Vascular Differentiation and Assembly 2011. [DOI: 10.1007/978-1-4419-7835-6_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
294 Cai J, Han S, Qing R, Liao D, Law B, Boulton ME. In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci (Landmark Ed) 2011;16:803-14. [PMID: 21196204 DOI: 10.2741/3721] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
295 Brem S, Wong ET. Angiogenesis and Brain Tumors. Youmans Neurological Surgery 2011. [DOI: 10.1016/b978-1-4160-5316-3.00106-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
296 Davis GE, Stratman AN, Sacharidou A, Koh W. Molecular basis for endothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting. Int Rev Cell Mol Biol 2011;288:101-65. [PMID: 21482411 DOI: 10.1016/B978-0-12-386041-5.00003-0] [Cited by in Crossref: 131] [Cited by in F6Publishing: 142] [Article Influence: 11.9] [Reference Citation Analysis]
297 Huyck T, Agulnik M. Molecular Therapies in Thyroid Cancer. Pharmaceuticals 2011;4:91-100. [DOI: 10.3390/ph4010091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
298 Lu-Emerson C, Norden AD, Drappatz J, Quant EC, Beroukhim R, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Wen PY. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol 2011;104:287-91. [PMID: 21153679 DOI: 10.1007/s11060-010-0489-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
299 Lemasson B, Christen T, Tizon X, Farion R, Fondraz N, Provent P, Segebarth C, Barbier EL, Genne P, Duchamp O, Remy C. Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. NMR Biomed 2011;24:473-82. [PMID: 21674650 DOI: 10.1002/nbm.1611] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
300 Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Casey T, Tsirigos A, Migneco G, Witkiewicz A, Balliet R, Mercier I, Wang C, Flomenberg N, Howell A, Lin Z, Caro J, Pestell RG, Sotgia F, Lisanti MP. The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. Cell Cycle 2010;9:4297-306. [PMID: 21051947 DOI: 10.4161/cc.9.21.13817] [Cited by in Crossref: 127] [Cited by in F6Publishing: 131] [Article Influence: 10.6] [Reference Citation Analysis]
301 Escorcia FE, Henke E, McDevitt MR, Villa CH, Smith-Jones P, Blasberg RG, Benezra R, Scheinberg DA. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 2010;70:9277-86. [PMID: 21045141 DOI: 10.1158/0008-5472.CAN-10-2029] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
302 Fuster MM, Wang L. Endothelial heparan sulfate in angiogenesis. Prog Mol Biol Transl Sci 2010;93:179-212. [PMID: 20807646 DOI: 10.1016/S1877-1173(10)93009-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
303 Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A, Witkiewicz A, Lin Z, Balliet R, Howell A. Understanding the “lethal” drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther. 2010;10:537-542. [PMID: 20861671 DOI: 10.4161/cbt.10.6.13370] [Cited by in Crossref: 140] [Cited by in F6Publishing: 149] [Article Influence: 11.7] [Reference Citation Analysis]
304 Ward C, Kuehn D, Burden RE, Gormley JA, Jaquin TJ, Gazdoiu M, Small D, Bicknell R, Johnston JA, Scott CJ, Olwill SA. Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One 2010;5:e12543. [PMID: 20824056 DOI: 10.1371/journal.pone.0012543] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
305 Ackerman R, Backer JM, Backer M, Skariah S, Hamby CV. SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model. Toxins (Basel) 2010;2:2242-57. [PMID: 22069683 DOI: 10.3390/toxins2092242] [Reference Citation Analysis]
306 Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, Vethanayagam RR, Singh S, Mohler JL, Smith GJ. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab 2011;300:E263-75. [PMID: 20699437 DOI: 10.1152/ajpendo.00210.2010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
307 Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010;9:2793-802. [PMID: 20699227 DOI: 10.1158/1535-7163.MCT-10-0477] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
308 Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15:819-25. [PMID: 20688807 DOI: 10.1634/theoncologist.2009-0317] [Cited by in Crossref: 109] [Cited by in F6Publishing: 123] [Article Influence: 9.1] [Reference Citation Analysis]
309 Cao Y. Off-tumor target--beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol 2010;7:604-8. [PMID: 20683436 DOI: 10.1038/nrclinonc.2010.118] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
310 Banerjee S, Cunningham D. Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. Clin Colorectal Cancer 2010;9 Suppl 1:S28-35. [PMID: 20630848 DOI: 10.3816/CCC.2010.s.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
311 Korpanty G, Sullivan LA, Smyth E, Carney DN, Brekken RA. Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol 2010;2010:652320. [PMID: 20628530 DOI: 10.1155/2010/652320] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
312 Coriat R, Ropert S, Mir O, Billemont B, Chaussade S, Massault PP, Blanchet B, Vignaux O, Goldwasser F. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs. 2011;29:1090-1093. [PMID: 20524036 DOI: 10.1007/s10637-010-9458-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
313 Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 2010;9:1525-35. [PMID: 20501804 DOI: 10.1158/1535-7163.MCT-09-1106] [Cited by in Crossref: 135] [Cited by in F6Publishing: 145] [Article Influence: 11.3] [Reference Citation Analysis]
314 Nussenbaum F, Herman IM. Tumor angiogenesis: insights and innovations. J Oncol. 2010;2010:132641. [PMID: 20445741 DOI: 10.1155/2010/132641] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 5.4] [Reference Citation Analysis]
315 Reynolds AR. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response 2010;8:253-84. [PMID: 20877487 DOI: 10.2203/dose-response.09-049.Reynolds] [Cited by in Crossref: 70] [Cited by in F6Publishing: 82] [Article Influence: 5.8] [Reference Citation Analysis]
316 Kerbel RS. Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast. 2009;18 Suppl 3:S41-S47. [PMID: 19914541 DOI: 10.1016/s0960-9776(09)70271-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
317 Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci USA. 2010;107:8363-8368. [PMID: 20404138 DOI: 10.1073/pnas.0911378107] [Cited by in Crossref: 255] [Cited by in F6Publishing: 276] [Article Influence: 21.3] [Reference Citation Analysis]
318 Gangjee A, Zaware N, Raghavan S, Ihnat M, Shenoy S, Kisliuk RL. Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. J Med Chem 2010;53:1563-78. [PMID: 20092323 DOI: 10.1021/jm9011142] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
319 Grépin R, Pagès G. Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol 2010;2010:835680. [PMID: 20224655 DOI: 10.1155/2010/835680] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
320 Li X, Zhao Z, Gao L. Regulation and Expression of Tagln2 in Early Rabbit Pregnant Uterus. Journal of Reproduction and Contraception 2010;21:27-34. [DOI: 10.1016/s1001-7844(10)60011-9] [Reference Citation Analysis]
321 You WK, Kasman I, Hu-Lowe DD, McDonald DM. Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels. Am J Pathol 2010;176:1927-40. [PMID: 20185574 DOI: 10.2353/ajpath.2010.090561] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
322 Moon JJ, Saik JE, Poché RA, Leslie-Barbick JE, Lee SH, Smith AA, Dickinson ME, West JL. Biomimetic hydrogels with pro-angiogenic properties. Biomaterials 2010;31:3840-7. [PMID: 20185173 DOI: 10.1016/j.biomaterials.2010.01.104] [Cited by in Crossref: 285] [Cited by in F6Publishing: 236] [Article Influence: 23.8] [Reference Citation Analysis]
323 Yang SX. Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev Anticancer Ther 2009;9:1715-25. [PMID: 19954282 DOI: 10.1586/era.09.153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
324 Das S, Ladell DS, Podgrabinska S, Ponomarev V, Nagi C, Fallon JT, Skobe M. Vascular endothelial growth factor-C induces lymphangitic carcinomatosis, an extremely aggressive form of lung metastases. Cancer Res 2010;70:1814-24. [PMID: 20179201 DOI: 10.1158/0008-5472.CAN-09-3675] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
325 Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Schultz L, Mikkelsen T. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 2010;99:237-42. [PMID: 20151176 DOI: 10.1007/s11060-010-0121-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 5.1] [Reference Citation Analysis]
326 Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, van Herpen CM. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 2009;48:927-31. [PMID: 19452305 DOI: 10.1080/02841860902974167] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
327 Yao LC, Baluk P, Feng J, McDonald DM. Steroid-resistant lymphatic remodeling in chronically inflamed mouse airways. Am J Pathol 2010;176:1525-41. [PMID: 20093490 DOI: 10.2353/ajpath.2010.090909] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
328 Liu Y, Carson-Walter EB, Cooper A, Winans BN, Johnson MD, Walter KA. Vascular gene expression patterns are conserved in primary and metastatic brain tumors. J Neurooncol 2010;99:13-24. [PMID: 20063114 DOI: 10.1007/s11060-009-0105-0] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 5.7] [Reference Citation Analysis]
329 Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke S, Meengs B, Brody J, Presnell S, Hamacher NB, Lantry M, Wolf A, Bukowski T, Rosler R, Yen C, Anderson-Haley M, Brasel K, Pan Q, Franklin H, Thompson P, Dodds M, Underwood S, Peterson S, Sivakumar PV, Snavely M. A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. MAbs 2010;2:20-34. [PMID: 20065654 DOI: 10.4161/mabs.2.1.10498] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
330 Dougherty GJ, Chaplin DJ. Development of Vascular Disrupting Agents. Vascular Disruptive Agents for the Treatment of Cancer 2010. [DOI: 10.1007/978-1-4419-6609-4_1] [Reference Citation Analysis]
331 Matsuo K, Lu C, Shazad MMK, Coleman RL, Sood AK. Role of Pericytes in Resistance to Antiangiogenic Therapy. The Tumor Microenvironment 2010. [DOI: 10.1007/978-1-4419-6615-5_15] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
332 Cao Y. Cancer Therapy by Targeting Vascular Endothelial Cell Growth Factor- and Non-Vascular Endothelial Cell Growth Factor-Mediated Angiogenesis. Therapeutic Angiogenesis for Vascular Diseases 2010. [DOI: 10.1007/978-90-481-9495-7_5] [Reference Citation Analysis]
333 Horn L, Sandler A. Angiogenesis Inhibitors in Lung Cancer. Lung Cancer 2010. [DOI: 10.1007/978-1-60761-524-8_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
334 Gupta S, McGrath B, Cavener DR. PERK regulates the proliferation and development of insulin-secreting beta-cell tumors in the endocrine pancreas of mice. PLoS One 2009;4:e8008. [PMID: 19956728 DOI: 10.1371/journal.pone.0008008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
335 Sennino B, Raatschen HJ, Wendland MF, Fu Y, You WK, Shames DM, McDonald DM, Brasch RC. Correlative dynamic contrast MRI and microscopic assessments of tumor vascularity in RIP-Tag2 transgenic mice. Magn Reson Med 2009;62:616-25. [PMID: 19526501 DOI: 10.1002/mrm.22040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
336 Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-6. [PMID: 19822869 DOI: 10.1212/WNL.0b013e3181bc0184] [Cited by in Crossref: 218] [Cited by in F6Publishing: 241] [Article Influence: 16.8] [Reference Citation Analysis]
337 Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5:610-20. [PMID: 19826401 DOI: 10.1038/nrneurol.2009.159] [Cited by in Crossref: 181] [Cited by in F6Publishing: 191] [Article Influence: 13.9] [Reference Citation Analysis]
338 Hedlund EM, Hosaka K, Zhong Z, Cao R, Cao Y. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc Natl Acad Sci U S A 2009;106:17505-10. [PMID: 19805167 DOI: 10.1073/pnas.0908026106] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 4.2] [Reference Citation Analysis]
339 Almulki L, Noda K, Nakao S, Hisatomi T, Thomas KL, Hafezi-Moghadam A. Localization of vascular adhesion protein-1 (VAP-1) in the human eye. Exp Eye Res 2010;90:26-32. [PMID: 19761765 DOI: 10.1016/j.exer.2009.09.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
340 Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res. 2009;15:5020-5025. [PMID: 19671869 DOI: 10.1158/1078-0432.ccr-09-0095] [Cited by in Crossref: 223] [Cited by in F6Publishing: 231] [Article Influence: 17.2] [Reference Citation Analysis]
341 Wolter P, Beuselinck B, Pans S, Schöffski P. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 2009;48:621-4. [PMID: 19107622 DOI: 10.1080/02841860802609574] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
342 Pichler J. Antiangiogenic therapy in malignant gliomas. memo 2009;2:10-12. [DOI: 10.1007/s12254-009-0124-8] [Reference Citation Analysis]
343 Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415-428. [PMID: 19461667 DOI: 10.1038/nrc2644] [Cited by in Crossref: 947] [Cited by in F6Publishing: 1022] [Article Influence: 72.8] [Reference Citation Analysis]
344 Sun WL, Hutarew G, Gradl J, Gratzl M, Heumader E, Denz H, Fiegl M. Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei. memo 2009;2:113-115. [DOI: 10.1007/s12254-009-0113-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
345 Schneider BP, Sledge GW Jr. Anti-VEGF therapy as adjuvant therapy: clouds on the horizon? Breast Cancer Res 2009;11:303. [PMID: 19519950 DOI: 10.1186/bcr2250] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
346 Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer. 2009;100:1704-1719. [PMID: 19436303 DOI: 10.1038/sj.bjc.6605061] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 5.8] [Reference Citation Analysis]
347 Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res 2009;69:4527-36. [PMID: 19401451 DOI: 10.1158/0008-5472.CAN-08-3779] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
348 Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, Saya H, Suda T. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009;206:1089-102. [PMID: 19398755 DOI: 10.1084/jem.20081605] [Cited by in Crossref: 275] [Cited by in F6Publishing: 282] [Article Influence: 21.2] [Reference Citation Analysis]
349 Ahn GO, Brown JM. Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives. Cell Cycle 2009;8:970-6. [PMID: 19270527 DOI: 10.4161/cc.8.7.8075] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
350 Stratman AN, Saunders WB, Sacharidou A, Koh W, Fisher KE, Zawieja DC, Davis MJ, Davis GE. Endothelial cell lumen and vascular guidance tunnel formation requires MT1-MMP-dependent proteolysis in 3-dimensional collagen matrices. Blood 2009;114:237-47. [PMID: 19339693 DOI: 10.1182/blood-2008-12-196451] [Cited by in Crossref: 171] [Cited by in F6Publishing: 186] [Article Influence: 13.2] [Reference Citation Analysis]
351 Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-239. [PMID: 19249681 DOI: 10.1016/j.ccr.2009.01.021] [Cited by in Crossref: 1354] [Cited by in F6Publishing: 1221] [Article Influence: 104.2] [Reference Citation Analysis]
352 Channual J, Choi B, Osann K, Pattanachinda D, Lotfi J, Kelly KM. Vascular effects of photodynamic and pulsed dye laser therapy protocols. Lasers Surg Med 2008;40:644-50. [PMID: 18951421 DOI: 10.1002/lsm.20673] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
353 Bukowski RM. Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer. Curr Oncol Rep 2009;11:81-3. [PMID: 19216838 DOI: 10.1007/s11912-009-0013-7] [Reference Citation Analysis]
354 Kutcher ME, Herman IM. The pericyte: cellular regulator of microvascular blood flow. Microvasc Res 2009;77:235-46. [PMID: 19323975 DOI: 10.1016/j.mvr.2009.01.007] [Cited by in Crossref: 112] [Cited by in F6Publishing: 90] [Article Influence: 8.6] [Reference Citation Analysis]
355 Phelps EA, Garcia AJ. Update on therapeutic vascularization strategies. Regen Med. 2009;4:65-80. [PMID: 19105617 DOI: 10.2217/17460751.4.1.65] [Cited by in Crossref: 107] [Cited by in F6Publishing: 109] [Article Influence: 8.2] [Reference Citation Analysis]
356 Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009;27:533-539. [PMID: 19145434 DOI: 10.1007/s00345-008-0368-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 4.2] [Reference Citation Analysis]
357 Seagroves TN. The Complexity of the HIF-1-Dependent Hypoxic Response in Breast Cancer Presents Multiple Avenues for Therapeutic Intervention. Pharmaceutical Perspectives of Cancer Therapeutics 2009. [DOI: 10.1007/978-1-4419-0131-6_16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
358 Schott M. Axitinib is an Active Treatment for all Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. Yearbook of Endocrinology 2009;2009:132-134. [DOI: 10.1016/s0084-3741(09)79274-1] [Reference Citation Analysis]
359 Backer MV, Hamby CV, Backer JM. Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature. Adv Genet 2009;67:1-27. [PMID: 19914448 DOI: 10.1016/S0065-2660(09)67001-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
360 Lakatos G, Tulassay Z. [Antiangiogenic therapy for gastrointestinal tumors]. Orv Hetil 2008;149:2317-24. [PMID: 19042183 DOI: 10.1556/OH.2008.28496] [Reference Citation Analysis]
361 Hlushchuk R, Riesterer O, Baum O, Wood J, Gruber G, Pruschy M, Djonov V. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol 2008;173:1173-85. [PMID: 18787105 DOI: 10.2353/ajpath.2008.071131] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 6.6] [Reference Citation Analysis]
362 Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, Ran S. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 2008;10:613-23. [PMID: 18516298 DOI: 10.1593/neo.08302] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
363 Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603. [PMID: 18650835 DOI: 10.1038/nrc2442] [Cited by in Crossref: 2080] [Cited by in F6Publishing: 2241] [Article Influence: 148.6] [Reference Citation Analysis]
364 Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol 2008;10:700-8. [PMID: 18697955 DOI: 10.1215/15228517-2008-042] [Cited by in Crossref: 52] [Cited by in F6Publishing: 62] [Article Influence: 3.7] [Reference Citation Analysis]
365 Grothey A, Arnold D, Ellis LM. Should bevacizumab be continued beyond progression in colorectal cancer? Curr colorectal cancer rep 2008;4:139-143. [DOI: 10.1007/s11888-008-0023-0] [Reference Citation Analysis]
366 Segarra M, Williams CK, Sierra Mde L, Bernardo M, McCormick PJ, Maric D, Regino C, Choyke P, Tosato G. Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood 2008;112:1904-11. [PMID: 18577711 DOI: 10.1182/blood-2007-11-126045] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
367 Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13. [PMID: 18541897 DOI: 10.1200/JCO.2007.15.9566] [Cited by in Crossref: 468] [Cited by in F6Publishing: 508] [Article Influence: 33.4] [Reference Citation Analysis]
368 Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039-2049. [PMID: 18463380 DOI: 10.1056/nejmra0706596] [Cited by in Crossref: 1628] [Cited by in F6Publishing: 1783] [Article Influence: 116.3] [Reference Citation Analysis]
369 Grossi F, Brianti A, Defferrari C, Pronzato P. Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations. memo 2008;1:13-16. [DOI: 10.1007/s12254-008-0005-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
370 Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS, Karumanchi SA, D'Amore PA. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008;205:491-501. [PMID: 18268040 DOI: 10.1084/jem.20072041] [Cited by in Crossref: 138] [Cited by in F6Publishing: 146] [Article Influence: 9.9] [Reference Citation Analysis]
371 Mcdonald DM. Angiogenesis and Vascular Remodeling in Inflammation and Cancer: Biology and Architecture of the Vasculature. Angiogenesis 2008. [DOI: 10.1007/978-0-387-71518-6_2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
372 Bast RC, Mills GB. Molecular Pathogenesis of Epithelial Ovarian Cancer. The Molecular Basis of Cancer 2008. [DOI: 10.1016/b978-141603703-3.10034-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
373 Baluk P, Falcón BL, Hashizume H, Sennino B, Mcdonald DM. Cellular Actions of Angiogenesis Inhibitors on Blood Vessels. Tumor Angiogenesis. [DOI: 10.1007/978-3-540-33177-3_32] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
374 Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Bråkenhielm E, Cao Y. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007;117:2766-77. [PMID: 17909625 DOI: 10.1172/JCI32479] [Cited by in Crossref: 209] [Cited by in F6Publishing: 225] [Article Influence: 13.9] [Reference Citation Analysis]
375 . Erratum. Journal of Cellular and Molecular Medicine 2008;12:355-60. [DOI: 10.1111/j.1582-4934.2008.00237.x] [Reference Citation Analysis]
376 Stan RV. Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis. J Cell Mol Med 2007;11:621-43. [PMID: 17760829 DOI: 10.1111/j.1582-4934.2007.00075.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 5.9] [Reference Citation Analysis]
377 Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007;117:2362-2368. [PMID: 17786229 DOI: 10.1172/jci32239] [Cited by in Crossref: 483] [Cited by in F6Publishing: 507] [Article Influence: 32.2] [Reference Citation Analysis]
378 Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA. 2007;104:17069-17074. [PMID: 17942672 DOI: 10.1073/pnas.0708148104] [Cited by in Crossref: 299] [Cited by in F6Publishing: 316] [Article Influence: 19.9] [Reference Citation Analysis]
379 Sennino B, Falcón BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res. 2007;67:7358-7367. [PMID: 17671206 DOI: 10.1158/0008-5472.CAN-07-0293] [Cited by in Crossref: 115] [Cited by in F6Publishing: 122] [Article Influence: 7.7] [Reference Citation Analysis]
380 Farha S, Asosingh K, Laskowski D, Licina L, Sekiguchi H, Losordo DW, Dweik RA, Wiedemann HP, Erzurum SC. Pulmonary gas transfer related to markers of angiogenesis during the menstrual cycle. J Appl Physiol (1985) 2007;103:1789-95. [PMID: 17717117 DOI: 10.1152/japplphysiol.00614.2007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
381 Choi B, Jia W, Channual J, Kelly KM, Lotfi J. The importance of long-term monitoring to evaluate the microvascular response to light-based therapies. J Invest Dermatol 2008;128:485-8. [PMID: 17657245 DOI: 10.1038/sj.jid.5700991] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
382 Spaide RF. Combination Therapies for Choroidal Neovascularization. Essentials in Ophthalmology. [DOI: 10.1007/978-3-540-33672-3_6] [Reference Citation Analysis]
383 Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res 2007;74:100-13. [PMID: 17532010 DOI: 10.1016/j.mvr.2007.03.004] [Cited by in Crossref: 134] [Cited by in F6Publishing: 142] [Article Influence: 8.9] [Reference Citation Analysis]
384 Singh Jaggi J, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, McDevitt MR, Nolan D, Mittal V, Benezra R, Scheinberg DA. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One 2007;2:e267. [PMID: 17342201 DOI: 10.1371/journal.pone.0000267] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
385 Naumov GN, Watnick RS, Almog N, Akslen LA, Folkman J. Response: Re: A Model of Human Tumor Dormancy: An Angiogenic Escape From the Nonangiogenic Phenotype. JNCI Journal of the National Cancer Institute 2007;99:331-332. [DOI: 10.1093/jnci/djk056] [Reference Citation Analysis]
386 Wang FE, Shi G, Niesman MR, Rewolinski DA, Miller SS. Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye. Exp Eye Res 2007;84:922-33. [PMID: 17399700 DOI: 10.1016/j.exer.2007.01.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
387 Thébaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med 2007;175:978-85. [PMID: 17272782 DOI: 10.1164/rccm.200611-1660PP] [Cited by in Crossref: 409] [Cited by in F6Publishing: 421] [Article Influence: 27.3] [Reference Citation Analysis]
388 Red-Horse K, Ferrara N. Imaging tumor angiogenesis. J Clin Invest 2006;116:2585-7. [PMID: 17016553 DOI: 10.1172/JCI30058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
389 Choi B, Jia W, Channual J, Kelly KM, Lotfi J. Rapid Therapy Evaluation Using Chronic, Wide-Field Optical Imaging of Microvascular Blood Flow Dynamics. Frontiers in Optics 2007/Laser Science XXIII/Organic Materials and Devices for Displays and Energy Conversion 2007. [DOI: 10.1364/fio.2007.fwe5] [Reference Citation Analysis]
390 Tyagi P, Grothey A. Commentary on a Phase III Trial of Bevacizumab plus XELOX or FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer: The NO16966 Trial. Clinical Colorectal Cancer 2006;6:261-264. [DOI: 10.3816/ccc.2006.n.044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
391 Mccarthy N. Barking up the right tree. Nat Rev Cancer 2006;6:828-828. [DOI: 10.1038/nrc2017] [Reference Citation Analysis]